

References

1. **A. G. RAJASRI1, R. SRESTHA1 & J. MITCHELL.** Acute fatty liver of pregnancy (AFLP) – an overview – journal of obstetrics and Gynaecology, April 2007; (3) 237-240 .
2. **Aarnoudse JG, Houthoff HJ, Weits J, Vellenga E, Huisjes HJ:** A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study. *Br J Obstet Gynaecol* 1986, 93:145-155.
3. **Abalos E, Duley L, Steyn DW, Henderson-Smart DJ.** Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Review. *Cochrane Database Syst Rev* 2007;1. CD002252.
4. **Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM:** Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? *Am J Obstet Gynecol* 1999, 180:221-225.
5. **Aceti A, Pasquazzi C, Zechini B, et al.** Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. *J Acquir Immune Defic Syndr* 2002; 29: 41–8.
6. **Aggarwal N, Sawney H, Suril V, Vasishta K, Jha M, Dhiman RK.** Pregnancy and cirrhosis of the liver. *Aust N Z J Obstet Gynaecol* 1999; 39: 503–06.
7. **Ahlawat SK, Lewis JH.** Tuberculosis of the liver, biliary tract and pancreas. In. *Tuberculosis and Nontuberculous Mycobacterial*

- Infections by Schlossberg D, ed 5th edn. New York, USA: McGraw-Hill, 2005: 290–324.
8. **Aldemir M, Bac B, Tacyildiz I, Yagmur Y, Keles C:** Spontaneous liver hematoma and a hepatic rupture in HELLP syndrome: report of two cases. *Surg Today* 2002, 32:450-453.
 9. **Alexander JM, Ramus R, Jackson G, Sercely B, Wendel Jr G.** Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. *Infect Dis Obstet Gynecol* 1999; 7: 283–6.
 10. **Almdal T.P., Sorensen T.I.** Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. *Hepatology* (1991) 13 650–655.
 11. **Altamura C, Vasapollo B, Tibuzzi F, Novelli GP, Valensise H, Rossini PM, Vernieri F:** Postpartum cerebellar infarction and haemolysis, elevated liver enzymes, low platelet (HELLP) syndrome. *Neurol Sci* 2005, 26:40-42.
 12. **Alter MJ.** Epidemiology of hepatitis B in Europe and worldwide. *J Hepatol* 2003; 39(Suppl. 1): 64–9.
 13. **Alvarez SZ, Carpio R.** Hepatobiliary tuberculosis. *Dig Dis Sci* 1983; 28: 193– 200.
 14. **Amorim MM, Santos LC, Faundes A:** Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. *Am J Obstet Gynecol* 1999, 180:1283-1288..
 15. **Andrade R.J., Lucena M.I., Ferná'ndez M.C. et al.** Drug- Induced Liver Injury: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. *Gastroenterology* (2005) 129 512–521...
 16. **Andrade RJ, Lucena MI, Garcia-Cortes M, et al.** Chronic hepatitis C, ibuprofen, and liver damage. *Am J Gastroenterol* 2002; 97: 1854–5.

17. **Araujo AC, Leao MD, Nobrega MH, Bezerra PF, Pereira FV, Dantas EM, Azevedo GD, Jeronimo SM:** Characteristics and treatment of hepatic rupture caused by HELLP syndrome. *Am J Obstet Gynecol* 2006, 195:129-133.
18. **Armani A, Toth PP.** Colesevelam hydrochloride in the management of dyslipidemia. *Expert Rev Cardiovasc Ther* 2006; 4: 283–91.
19. **Armenti VT, Radomski JS, Moritz MJ, et al.** Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. *Clin Transpl* 2005; 69–83.
20. **Armstrong GL, Perz JF, Alter MJ:** Perinatal hepatitis C virus transmission: role of human immunodeficiency virus infection and injection drug use. *J Infect Dis* 2003, 187:872–874.
21. **Asherson RA, Schamroth-Rapaport N, Skudowitz B, Singh S, Marx D, Miesbach W:** Recurrent deep vein thrombosis, ovarian carcinoma and antibodies to mitochondria M5 in a patient with asymptomatic primary "plus" antiphospholipid syndrome: an unusual combination. *Clin Exp Rheumatol* 2007, 25:890-895.
22. **Asker C, Norstedt Wikner B & Kallen B.** Use of antiemetic drugs during pregnancy in Sweden. *Eur J Clin Pharmacol* 2005; 61(12): 899–906.
23. **Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group.** Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. *Lancet* 2007;369:1765–6.
24. **Aslan H, Gul A, Cebeci A:** Neonatal outcome in pregnancies after preterm delivery for HELLP syndrome. *Gynecol Obstet Invest* 2004, 58:96-99.
25. **Asmuth DM, Busch MP, Laycock ME, et al.:** Hepatitis B and C viral load changes following initiation of highly active antiretroviral

- therapy (HAART) in patients with advanced HIV infection. *Antiviral Res* 2004, 63:123–131.
- 26. Atanackovic G, Navioz Y, Moretti ME et al.** The safety of higher than standard dose of doxylaminepyridoxine (Diclectin) for nausea and vomiting of pregnancy. *J Clin Pharmacol* 2001; 41(8): 842–845.
- 27. Audibert F, Friedman SA, Frangieh AY, Sibai BM:** Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. *Am J Obstet Gynecol* 1996, 175:460-464.
- 28. August P, Lindheimer M.** Chronic hypertension and pregnancy. In: *Hypertensive Disorders in Pregnancy* by Lindheimer MD, Roberts JM, Cunningham FG, editors. Chesley's, 2nd ed. Stamford, Connecticut: Appleton & Lange; 1999:605–33.
- 29. Bachs L, Pares A, Elena M, et al.** Effects of long term rifampicin administration in primary biliary cirrhosis. *Gastroenterology* 1992; 102: 2077–80.
- 30. Bacq Y, Gendrot C, Perrotin F, et al.** ABCB4 gene mutations and singlenucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. *J Med Genet* 2009; 46:711–715.
- 31. Bacq Y, Riely CA. 1993.** Acute fatty liver of pregnancy: the hepatologist's view. *Gastroenterologist* 1:257 – 264.
- 32. Bagheri H., Michel F., Lapeyre-Mestre M. et al.** Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. *Br. J. Clin. Pharmacol.* (2000) 50 479–484.
- 33. Bagis T, Gumurdulu Y, Kayaselcuk F et al.** Endoscopy in hyperemesis gravidarum and *Helicobacter pylori* infection. *Int J Gynaecol Obstet* 2002; 79(2): 105–109.

34. **Bai H, Zhang L, Ma L, et al.** Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intrauterine transmission mechanism. *World J Gastroenterol* 2007; 13: 3625–30...
35. **Baker PN, Cunningham FG.** Platelet and coagulation abnormalities. In: Lindheimer MD, Roberts JM, Cunningham FG, editors. *Chesley's Hypertensive Disorders in Pregnancy*. 2nd ed. Stamford, Connecticut: Appleton & Lange; 1999:349–75 (3rd edition revision in press, May 2009, Elsevier).
36. **Baldwin GS. 2000.** Do NSAIDS contribute to acute fatty liver of pregnancy? *Medical Hypothesis* 54:846 – 849.
37. **Balzarini J, Lee C, Herdewijn P, et al.** Mechanism of the potentiating effect of ribavirin on the activity of 2',3'- dideoxyinosine against human immunodeficiency virus. *J Biol Chem* 1991; 266:21509–14.
38. **Banait VS, Sandur V, Parikh F, et al.** Outcome of acute liver failure due to acute hepatitis E in pregnant women. *Indian J Gastroenterol* 2007; 26: 6–10.
39. **Banks AT, Zimmerman HJ, Ishai LG, et al.** Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration. *Hepatology* 1995; 22: 820–5.
40. **Banks BA, Cnaan A, Morgan MA, Parer JT, Merrill JD, Ballard PL, Ballard RA:** Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. *Am J Obstet Gynecol* 1999, 181:709-717.
41. **Banks BA, Macones G, Cnaan A, Merrill JD, Ballard PL, Ballard RA:** Multiple courses of antenatal corticosteroids are associated with early severe lung disease in preterm neonates. *J Perinatol* 2002, 22:101-107.

- 42. Barrilleaux PS, Martin JN Jr, Klauser CK, Bufkin L, May WL:** Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: a randomized trial. *Obstet Gynecol* 2005, 105:843-848..
- 43. Bartels S, Sivilotti M, Crosby D, et al.** Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial. *Clin Toxicol* 2008; 40: 243–9.
- 44. Barton JR, Sibai BM, Mabie WC, Shanklin DR. 1990.** Recurrent acute fatty liver of pregnancy. *American Journal of Obstetrics and Gynecology* 163:534 - 538.
- 45. Barton JR, Sibai BM.** Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome. *Clin Perinatol* 2004;31:807–33,
- 46. Barton JR, Sibai BM:** Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome. *Clin Perinatol* 2004, 31:807-33.
- 47. Bashiri A, Neumann L, Maymon E et al.** Hyperemesis gravidarum: epidemiologic features, complications and outcome. *Eur J Obstet Gynecol Reprod Biol* 1995; 63(2): 135–138.
- 48. Basile AS, Jones EA.** Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. *Hepatology* 1997;25:1303– 1305.
- 49. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, Huon C, Lepercq J, Dehan M, Lacaze-Masmonteil T:** Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. *N Engl J Med* 1999, 341:1190-1196.

50. **Baxter JK, Weinstein L:** HELLP syndrome: the state of the art. *Obstet Gynecol Surv* 2004, 59:838-845.
51. **Bayraktaroglu Z, Demirci F, Balat O, Kutlar I, Okan V, Ugur G:** Plasma exchange therapy in HELLP syndrome: A singlecenter experience. *Turk J Gastroenterol* 2006, 17:99-102.
52. **Beasley RP, Stevens CE, Shiao IS, Meng HC, et al.** Evidence against breastfeeding as a mechanism for vertical transmission of hepatitis B. *Lancet* 1975; 2: 740–1.
53. **Beld M, Penning M, Lukashov V, et al.** Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. *Virology* 1998, 244:504–512.
54. **Belfort R, Harrison SA, et al.** A placebo- controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006; 355: 2297– 307.
55. **Benichou C., Danan G., Flahault A.** Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. *J. Clin. Epidemiol.* (1993) 46 1331–1336.
56. **Bergin PS & Harvey P.** Wernicke's encephalopathy and central pontine myelinolysis associated with hyperemesis gravidarum. *Br Med J* 1992; 305(6852): 517–518.
57. **Bhatia V, Singhal A, Panda SK, Acharya SK.** A 20-year single-center experience with acute liver failure during pregnancy: is the prognosis really worse? *Hepatology* 2008; 48: 1577–85.
58. **Bick RL:** Syndromes of disseminated intravascular coagulation in obstetrics, pregnancy, and gynecology. Objective criteria for diagnosis and management. *Hematol Oncol Clin North Am* 2000, 14:999-1044..

59. **Björnsön E., Ismael S., Nejdet S., Kilander A.** Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. *Scand. J. Gastroenterol.* (2003) 38 86–94.
60. **Blanco C, Maqueda E, Rubiio JA, Rodriquez A.** Cushing’s syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy. *J Endocrinol Invest* 2006;29:164–7..
61. **Boelsterli U.A., Lim P.L.K.** Mitochondrial abnormalities. A link to idiosyncratic drug hepatotoxicity? *Toxicol. Appl. Pharmacol.* (2007) 220 92–107.
62. **Brewer GJ, Johnson VD, Dick RD, Hedera P, Fink JK, Kluin KJ.** Treatment of Wilson’s disease with zinc. XVII: treatment during pregnancy. *Hepatology* 2000; 31: 364–70.
63. **Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, et al.** The detection, investigation and management of hypertension in pregnancy: executive summary. *Aust N Z J Obstet Gynaecol* 2000;40: 133–8.
64. **Browning JD.** Statins and hepatic steatosis: perspectives from the Dallas Heart Study. *Hepatology* 2006; 44: 466–71.
65. **Bruce RD, Altice FL.** Case series on the safe use of nuprenorphine / naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. *Am J Drug Alcohol Abuse* 2007; 33: 869–74.
66. **Brunt PW, Kew MC, Scheuer PJ, Sherlock S.** Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. *Gut* 1974; 15: 52–58.
67. **Brusco F, Gonzalez G, et al.** Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil- induced acute hepatic failure. *Thyroid* 2004; 14: 862–5.

68. **Burk RD, Hwang LY, Ho GY, et al.** Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. *J Infect Dis* 1994; 170: 1418–23.
69. **Burneo J, Vizcarra D & Miranda H.** Central pontine myelinolysis and pregnancy: a case report and review of literature. *Rev Neurol* 2000; 30(11): 1036–1040.
70. **Burroughs AK, Seong NH, Dojcinov DM et al.** Idiopathic acute fatty liver of pregnancy in 12 patients. *Q J Med* 1982; 51: 481–97
71. **Byrne JA, Strautnieks SS, Mieli-Vergani G, et al.** The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. *Gastroenterology* 2002; 123: 1649–58.
72. **Caldwell SH, Heapenheide EE, Redick JA, et al.** A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. *Am J Gastroenterol* 2001; 95: 519–25.
73. **Caldwell SH, Patrie JT, Brunt EM, et al.** The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. *Hepatology* 2007; 46: 1101–7.
74. **Canta F, Marrone R, Bonora S, et al.** Pharmacokinetics and hepatotoxicity of lopinavir / ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. *J Antimicrob Chemother* 2005; 55: 280–1.
75. **Capuzzi DM, Guyton JR, Morgan JM, et. al.** Efficacy and safety of extended release niacin (Niaspan): a long term study. *Am J Cardiol* 1998; 82: 74U–81U..
76. **Castro MA, Fasset MJ, Reynolds TB, Shaw KJ, Goodwin TM. 2000.** Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy based on 28 cases. *American Journal of Obstetrics and Gynecology* 181:389 – 395.

77. **Cavkaytar S, Ugurlu EN, Karaer A, Tapisiz OL, Danisman N:** Are clinical symptoms more predictive than laboratory parameters for adverse maternal outcome in HELLP syndrome? *Acta Obstet Gynecol Scand* 2007, 86:648-651.
78. **Ceci O, Margiotta M, Mareello F, et al.:** Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. *J Pediatr Gastroenterol Nutr* 2001, 33:570–575.
79. **Celik C, Gezgin K, Altintepe L, Tonbul HZ, Yaman ST, Akyurek C, Turk S:** Results of the pregnancies with HELLP syndrome. *Ren Fail* 2003, 25:613-618....
80. **Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD.** Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology* 2004; 126: 1287–92
81. **Chalasani N, Fontana R, Watkins PB, et al.** Drug Induced Liver Injury Network (DILIN) prospective study: initial results [abstract]. *Am J Gastroenterol* 2006; 101: S169.
82. **Chalasani N.** Statins and hepatotoxicity: focus on patients with fatty liver. *Hepatology* 2005; 41: 690–5. 33 .
83. **Chalasani N., Fontana R., Watkins P.B. et al.** Drug induced liver injury network (DILIN). Prospective study: initial results. *Am. J. Gastroenterol.* (2006) 101 S168.
84. **Chang MH, Chen CJ, Lai MS, et al.** Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med* 1997; 336: 1906–7.
85. **Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA.** Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. *Am J Med* 2005; 118: 618–24.

86. **Chen H-L, Chang C-J, Kong M-S, et al.** Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. *Hepatology* 2004; 39: 58–63.
87. **Chhabra S, Qureshi A, Datta N:** Perinatal outcome with HELLP/partial HELLP complicating hypertensive disorders of pregnancy. An Indian rural experience. *J Obstet Gynaecol* 2006, 26:531-533.
88. **Chiossi G, Neri I, Cavazzuti M et al.** Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. *Obstet Gynecol Surv* 2006; 61(4): 255–268.
89. **Cho FN, Chen SN, Kan YY, Lee TC, Wang JS:** Successful management of a pregnant woman with HELLP syndrome, pulmonary edema, postpartum hemorrhage and acute renal failure, using early hemodialysis, intravenous immunoglobulin and noninvasive monitoring: a case report. *J Reprod Med* 2007, 52:661-663.
90. **Choudhry NK, Avorn J.** Over-the-counter statins. *Ann Intern Med* 2005; 142: 910–3.
91. **Choy Y, Gittens-Williams L, Apuzzio J, et al.:** Risk factors for hepatitis C infection among sexually transmitted disease-infected, inner city obstetric patients. *Infect Dis Obstet Gynecol* 2003, 11:191–198.
92. **Christopher V, Al-Chalabi T, Richardson PD, et al.** Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. *Liver Transpl* 2006; 12: 1138–43.
93. **Cipolla MJ.** Cerebrovascular function in pregnancy and eclampsia. *Hypertension* 2007;50:14–24.
94. **Clements D, Young WT, Thornton JG, Rhodes J, Hayward C, Hibbard B. 1990.** Imaging in acute fatty liver of pregnancy – A case report. *British Journal of Obstetrics and Gynaecology* 97: 631 – 633.

- 95.Cobey FC, Salem RR.** A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. *Am J Surg* 2004; 187: 181–91.
- 96.Coghlan ME, Sommadossi JP, et al.** Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. *Clin Infect Dis* 2001; 33: 1914–21.
- 97.Cohen DE, Anania FA, Chalasani N.** National lipid association statin safety task force liver expert panel. An assessment of statin safety by hepatologists. *Am J Cardiol* 2006; 8(Suppl. 1): S77–81..
- 98.Conde-Agudelo A, Villar J, Lindheimer MD.** WHO systematic review of screening tests for prediction of preeclampsia. *Obstet Gynecol* 2004;104:1367–914.
- 99.Conrad KP, Lindheimer MD.** Renal and cardiovascular alterations. In: Lindheimer MD, Roberts JM, Cunningham FG, editors. *Chesley's Hypertensive Disorders in Pregnancy*. 2nd ed. Stamford, Connecticut: Appleton & Lange; 1999:263–326 (3rd edition revision in press, May 2009, Elsevier).
- 100. Conte D, Fraquelli M, Prati D, et al.:** Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. *Hepatology* 2000, 31:751–755.
- 101. Cooper WO, Hernandez-Diaz S, Arbogast PD, Dudley JA, Dyer S, Gideon PS, et al.** Major congenital anomalies after first-trimester exposure to ACE inhibitors. *N Engl J Med* 2006;354:2443–51.
- 102. Cowan SA, Bagdonaite J, Qureshi K.** Universal hepatitis B screening of pregnant women in Denmark ascertains substantial additional infections: results from the first five months. *Eurosurveillance* 2006; 11: pii–2969.

103. **Crowther CA, Doyle LW, Haslam RR, Hiller JE, Harding JE, Robinson JS:** Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. *N Engl J Med* 2007, 357:1179-1189.
104. **Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS:** Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. *Lancet* 2006, 367:1913-1919.
105. **Curtin WM, Weinstein L:** A review of HELLP syndrome. *Journal of Perinatology* 1999, 19:138-143.
106. **Curtin WM, Weinstein L:** A review of HELLP syndrome. *Journal of Perinatology* 1999, 19:138-143.
107. **Czeizel AE, Sarkozi A & Wyszynski DF.** Protective effect of hyperemesis gravidarum for nonsyndromic oral clefts. *Obstet Gynecol* 2003; 101(4): 737–744.
108. **Dalton T, Berry R.** Hepatotoxicity associated with sustained release niacin. *Am J Med* 1992; 93: 1992.
109. **Dani R, Mendes GS, Medeiros Jde L, Pe´ret FJ, Nunes A.** Study of the liver changes occurring in preeclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy. *Am J Gastroenterol* 1996;91:292–4.
110. **Darunavir** (Prezista) [package insert]. Gurabo (Puerto Rico): Tibotec, Inc., 2006.
111. **Das CJ, Srivastava DN, Debnath J, Ramchandran V, Pal S, Sahni P:** Endovascular management of hepatic hemorrhage and subcapsular hematoma in HELLP syndrome. *Indian J Gastroenterol* 2007, 26:244-245.
112. **De Abajo F., Montero D., Madurga M., Garcia Rodriguez L.A.** Acute and clinically relevant drug-induced liver injury: a population based case-control study. *Br. J. Clin. Pharmacol.* (2004) 58 71–80.

113. **de Belder A, Lees C, Martin J, Moncada S, Campbell S.** Treatment of HELLP syndrome with nitric oxide donor [Letter]. *Lancet* 1995;345:124–125.
114. **de Denus S, Spinler SA, Miller K, Peterson AM.** Statins and liver toxicity: a meta-analysis. *Pharmacotherapy* 2004; 24: 584–91. 24
115. **de la Rosa MA, Nicol´as-P´erez D, Mu˜niz-Montes JR, et al.** Evolution and management of a hepatocellular carcinoma during pregnancy. *J Obstet Gynaecol Res* 2006; 32: 437–9.
116. **De Martino M, Appendino C, Resti M, et al.** Should hepatitis B surface antigen positive mothers breast feed? *Arch Dis Child* 1985; 60: 972–4.
117. **de OliveriaCP, Stefano JT, De Siqueira ER, et al.** Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. *Hepatol Res* 2008; 38: 159–65.
118. **Dechend R, Homuth V, Wallukat G, Mu¨ller DN, Krause M, Dudenhausen J, et al.** Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. *J Soc Gynecol Invest* 2006;13:79–86.
119. **Deepak Joshi, Andra James, Alberto Quaglia, Rachel H Westbrook, Michael A Heneghan.** Liver disease in pregnancy – *lancet* 2010;375: 594-605.
120. **Dekker G, Robillard PY:** The birth interval hypothesis-does it really indicate the end of the primipaternity hypothesis. *J Reprod Immunol* 2003, 59:245-251.30.
121. **del Canho R, Grosheide PM, Mazel JA, et al.** Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity. *Vaccine* 1997; 15: 1624–30.

122. **Deledinghen V, Heresbach D, Fournan O, et al.** Anti-inflammatory drugs and variceal bleeding: a case-control study. *Gut* 1999; 44: 270–3.
123. **den Brinker M, Wit FW, Wertheim-van Dillen PM, et al.** Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. *AIDS* 2000; 14: 2895–902.
124. **Depue RH, Bernstein L, Ross RK et al.** Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. *Am J Obstet Gynecol* 1987; 156(5): 1137–1141.
125. **Deruelle P, Coudoux E, Ego A, Houfflin-Debarge V, Codaccioni X, Subtil D:** Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. *Eur J Obstet Gynecol Reprod Biol* 2006, 125:59-65.
126. **Detti L, Mecacci F, Piccioli A, Ferrarello S, Carignani L, Mello G, Ferguson JE, Scarselli G:** Postpartum heparin therapy for patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) is associated with significant hemorrhagic complications. *J Perinatol* 2005, 25:236-240.
127. **Devarbhavi H, Kremers WK, Dierkhising R, Padmanabhan L.** Pregnancy-associated acute liver disease and acute viral hepatitis: differentiation, course and outcome. *J Hepatol* 2008; 49: 930–35.
128. **Diagnosis and management of preeclampsia and eclampsia.** Number 33, January 2002. American College of Obstetricians and Gynecologists (ACOG) 2002;99:159–67..
129. **Dieterich DT, Robinson PA, Love J, et al.** Drug-induced liver injury associated with the use of nonnucleoside reverse transcriptase inhibitors. *Clin Infect Dis* 2004; 38(Suppl. 2): S80–9.

130. **Dieterich DT.** Special considerations and treatment of patients with HBV-HIV coinfection. *Antivir Ther* 2007; 12(Suppl. 3): H43–51.
131. **Dodds L, Fell DB, Joseph KS et al.** Outcomes of pregnancies complicated by hyperemesis gravidarum. *Obstet Gynecol* 2006; 107(2 Pt 1): 285–292.
132. **Doepel M, Backas HN, Taskinen EI, Isoniemi HM, Hockerstedt KA.** 1996. Spontaneous recovery of post partum liver necrosis in a patient listed for transplantation. *Hepatogastroenterology* 43:1084 – 1087.
133. **Dötsch J, Hohmann M, Kuhl PG:** Neonatal morbidity and mortality associated with maternal haemolysis elevated liver enzymes and low platelets syndrome. *Eur J Pediatr* 1997, 156:389-391.
134. **Drakeley AJ, Le Roux PA, Anthony J, Penny J:** Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit. *Am J Obstet Gynecol* 2002, 186:253-256.
135. **Dugas G, Fuller J, Singh S, Watson J.** Pheochromocytoma and pregnancy: a case report and review of anesthetic management. *Can J Anaesth* 2004;51:134–8.
136. **Duh M.S., Walker A.M., Kronlund K.H. Jr.** Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. *Pharmacoepidemiol. Drug Saf.* (1999) 8 275–283.
137. **Duley L, Henderson-Smart DJ, Meher S, King JF.** Antiplatelet agents for preventing preeclampsia and its complications. *Cochrane Database Syst Rev* 2007;2. CD004659.
138. **Egerman RS, Sibai BM:** HELLP syndrome. *Clin Obstet Gynecol* 1999, 42:381-389.
139. **Elefsiniotis IS, Pantazis KD, Ilias A, et al.** Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver

- steatosis: the role of glucose intolerance. *Eur J Gastroenterol Hepatol* 2004; 16: 593–8.
140. **Elinav E, Ben-Dov IZ, Shapira Y, et al.** Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. *Gastroenterology* 2006; 130: 1129–34.
 141. **Elinav E, Pinsker G, Safadi R, et al.** Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. *J Hepatol* 2007; 47: 514–20.
 142. **Ellison J, Sattar N, Greer I:** HELLP syndrome: mechanisms and management. *Hosp Med* 1999, 60:243-249.
 143. **Ertan AK, Wagner S, Hendrik HJ, Tanriverdi HA, Schmidt W:** Clinical and biophysical aspects of HELLP-syndrome. *J Perinat Med* 2002, 30:483-489.
 144. **Eser B, Guven M, Unal A, Coskun R, Altuntas F, Sungur M, Serin IS, Sari I, Cetin M:** The role of plasma exchange in HELLP syndrome. *Clin Appl Thromb Hemost* 2005, 11:211-217.
 145. **Euler GL, Wooten KG, Baughman AL, Williams WW.** Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. *Pediatrics* 2003; 111: 1192–7.
 146. **Fairweather DV.** Nausea and vomiting in pregnancy. *Am J Obstet Gynecol* 1968 Sep; 102(1): 135–175..
 147. **Farr RW, Short S, Weissman D.** Fulminant hepatitis during herpes simplex virus infection in apparently immunocompetent adults: report of two cases and review of the literature. *Clin Infect Dis* 1997;24: 1191–94.
 148. **FDA Draft Guidance for Industry.** Drug- Induced Liver Disease: Premarketing Clinical Evaluation. 2007, October. Available at:

<http://www.fda.gov/cder/guidance/7507dft.htm> (last accessed 19 August 2008).

149. **Feldman M, Friedman LS, Sleisenger MH.** Sleisenger & Fordtran's gastrointestinal and liver disease. 7th ed. Philadelphia, Saunders. 2002. pp 1227–1239, 1310–1311.
150. **Fell DB, Dodds L, Joseph KS et al.** Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy. *Obstet Gynecol* 2006; 107(2 Pt 1): 277–284.
151. **Ferrero S, Lungaro P, Bruzzone BM, et al.:** Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990–2000). *Acta Obstet Gynecol Scand* 2003, 82:229–234.
152. **Fesenmeier MF, Coppage KH, Lambers DS, Barton JR, Sibai BM. 2005.** Acute fatty liver of pregnancy in 3 tertiary care centers. *American Journal of Obstetrics and Gynecology* 192: 1416 – 1419.
153. **Fesenmeier MF, Coppage KH, Lambers DS, Barton JR, Sibai BM.** Acute fatty liver of pregnancy in 3 tertiary care centers. *Am J Obstet Gynecol* 2005; 192: 1416–19.
154. **Fischer-Rasmussen W, Kjaer SK & Dahl C.** Ginger treatment of hyperemesis gravidarum. *Eur J Obstet Gynecol Reprod Biol* 1991; 38(1): 19–24.
155. **Folk JJ, Leslie-Brown HF, Nosovitch JT et al.** Hyperemesis gravidarum: outcomes and complications with and without total parenteral nutrition. *J Reprod Med* 2004; 49(7): 497–502.
156. **Fonseca JE, Mendez F, Catano C, Arias F:** Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. *Am J Obstet Gynecol* 2005, 193:1591-1598.
157. **Franchini M:** Thrombotic microangiopathies: an update. *Hematology* 2006, 11:139-146.

158. **Fuks A, Mays J, Otuyelu-Garritano K, et al.** Labor induction in patients with intrahepatic cholestasis of pregnancy before 36 weeks. [abstract] *Obstet Gynecol* 2007;109;4:86S.
159. **Funai EF, Friedlander Y, Paltiel O, Tiram E, Xue X, Deutsch L, et al.** Long-term mortality after preeclampsia. *Epidemiology* 2005;16:206–15
160. **Garcia Rodriguez L.A., Ruigomez A., Jick H.** A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. *Pharmacotherapy* (1997) 17 721–728.
161. **Garcia-Cortes M., Lucena M.I., Pachkoria K. et al.** Evaluation of the Naranjo Adverse Drug Reactions Probability Scale in the Causality Assessment of Drug-Induced Liver Injury. *Alim. Pharmacol. Ther.* (2008) in press.
162. **Gartner LM, Morton J, Lawrence RA, et al.** American Academy of Pediatrics Section on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics* 2005; 115: 496–506.
163. **Geary M:** The HELLP syndrome. *Br J Obstet Gynaecol* 1997, 104:887-891.
164. **Geenes V, Williamson C.** Intrahepatic cholestasis of pregnancy. *World J Gastroenterol* 2009; 15:2049–2066..
165. **Gelotte CK, Temple AR, Zimmerman BA, Slattery JT** Acetaminophen biotransformation at single and repeat maximum doses is similar between adults with and without chronic liver disease. *Hepatology* 2007; 46(4 suppl.): 810A.
166. **Gerard Y, Maulin L, Yazdanpanah Y, et al.** Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. *AIDS* 2000; 14: 2723–30.

167. **Gervais A, Bacq Y, Bernuau J, et al.:** Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. *J Hepatol* 2000, 32:293–299.
168. **Giannubilo SR, Tranquilli AL, Santolini C, Principi F, Mancinelli R, Littarru GP:** Placental CoQ10 levels in HELLP syndrome. *Biofactors* 2005, 25:159-163.
169. **Gibb DM, Goodall RL, Dunn DT, et al.:** Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. *Lancet* 2000, 356:904–907.
170. **Gibson K, Rindone JP.** Experience with statin use in patients with chronic hepatitis C infection. *Am J Cardiol* 2005; 96: 1278–9.
171. **Gilbert WM, Young AL, Danielson B.** Pregnancy outcome in women with chronic hypertension: a population based study. *J Reprod Med* 2007;52:1046–51.
172. **Gilboa Y, Bardin R, Feldberg D, Bachar GN:** Postpartum hepatic rupture and retroperitoneal hematoma associated with HELLP syndrome. *Isr Med Assoc J* 2006, 8:219-220..
173. **Gitlin N. Salicylate hepatotoxicity.** The potential role of hypoalbuminemia. *J Clin Gastroenterol* 1980; 2: 883–4.
174. **Glantz A, Marschall HA, Mattsson LA.** Intrahepatic cholestasis of pregnancy: relationship between bile acids and fetal complication rates. *Hepatology* 2004;40:467– 474.
175. **Glantz A, Marschall HU, Mattsson LA.** Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. *Hepatology* 2004; 40:467–474.
176. **Goldman-Levine JD, Bohlman LG.** Ezetimibe / simvastatin (Vytorin) for hypercholesterolemia. *Am Fam Physician* 2005; 72: 2081–2.

177. **Goodlin RC:** Severe pre-eclampsia: another great imitator. *Am J Obstet Gynecol* 1976; 125:747-753.
178. **Goodwin TM, Montoro M & Mestman JH.** Transient hyperthyroidism and hyperemesis gravidarum: clinical aspects. *Am J Obstet Gynecol* 1992; 167(3): 648–652.
179. **Goodwin TM.** Nausea and vomiting of pregnancy: an obstetric syndrome. *Am J Obstet Gynecol* 2002; 186(5 Suppl Understanding): S184–S189.
180. **Gordon A, Hobbs DA, Bowden DS, et al.** Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. *J Gastroenterol Hepatol* 2006; 21: 275–80.
181. **Gorelik J, Harding SE, Shevchuk AL, et al.** Taurocholate induces changes in rat cardiomyocyte contraction and calcium dynamics. *Clin Sci (Lond)* 2002; 103:191–200.
182. **Gortner L, Pohlandt F, Bartmann P, Terinde R, Versmold H, Dorigo O:** Short-term outcome in infants with birth weights less than 1750 g born to mothers with HELLP syndrome. *J Perinat Med* 1992, 20:25-28.
183. **Gracia PV, Lavergne JA. 2001.** Acute fatty liver of pregnancy. *International Journal of Gynaecology and Obstetrics* 72:193 – 195.
184. **Gracia PV. 2001.** Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. *International Journal of Gynaecology and Obstetrics* 73:215 – 220.
185. **Green JL, Heard K, Bogdan GM, et al.** Treatment of alcoholic HCV patients with acetaminophen 4 g/day for 5 days does not affect hepatic tests compared to placebo. *Hepatology* 2007; 46(4 suppl.): 821A..

186. **Gresser U.** Amoxicillin-clavulanic acid therapy may be associated with severe side effects: review of the literature. *Eur J Med Res* 2001; 6: 139–49.
187. **Groot E, de Groot PG, Fijnheer R, Lenting PJ:** The presence of active von Willebrand factor under various pathological conditions. *Curr Opin Hematol* 2007, 14:284-289.
188. **Gul A, Aslan H, Cebeci A, Polat I, Ulusoy S, Ceylan Y:** Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure. *Ren Fail* 2004, 26:557-562.
189. **Gul A, Cebeci A, Aslan H, Polat I, Ozdemir A, Ceylan Y:** Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome. *Gynecol Obstet Invest* 2005, 59:113-118.
190. **Gupta I, Ratho RK.** Immunogenicity and safety of two schedules of hepatitis B vaccination during pregnancy. *J Obstet Gynaecol Res* 2003; 29: 84–6.
191. **Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM:** Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. *Am J Obstet Gynecol* 2000, 183:444-448.
192. **Haddad B, Sibai BM:** Expectant management of severe preeclampsia: proper candidates and pregnancy outcome. *Clin Obstet Gynecol* 2005, 48:430-440.
193. **Haeger M, Unander M, Norder-Hansson B, Tylman M, Bengtsson A:** Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. *Obstet Gynecol* 1992, 79:19-26.
194. **Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P.** Incidence and routes of transmission of hepatitis B virus in England

- and Wales, 1995–2000: implications for immunization policy. *J Clin Virol* 2004; 29: 211–20.
195. **Haram K, Softeland E, Hervig T, Pirhonen J:** Thrombocytopaenia in pregnancy. *Tidsskr Nor Laegeforen* 2003, 123:2250-2252.
196. **Harms K, Rath W, Herting E, Kuhn W:** Maternal hemolysis, elevated liver enzymes, low platelet count, and neonatal outcome. *Am J Perinatol* 1995, 12:1-6.
197. **Harskamp RE, Zeeman GG.** Preeclampsia: at risk for remote cardiovascular disease. *Am J Med Sci* 2007; 334:291–5.
198. **Hashiguchi K, Inamura T, Irita K, Abe M, Noda E, Yanai S, Takahashi S, Fukui M:** Late occurrence of diffuse cerebral swelling after intracerebral hemorrhage in a patient with the HELLP syndrome – Case report. *Neurol Med Chir (Tokyo)* 2001, 41:144-148.
199. **Hattori Y, Orito E, Ohno T, et al.:** Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection. *J Med Virol* 2003, 71:205–211.
200. **Hay JE.** Liver disease in pregnancy. *Hepatology* 2008; 47:1067–76.
201. **Healy CM, Cafferkey MT, Butler KM, et al.** Antenatal hepatitis B screening – is there a need for a national policy? *Irish Med J* 2001; 94: 111–2.
202. **Healy CM, Cafferkey MT, Conroy A, et al.:** Outcome of infants born to hepatitis C infected women. *Ir J Med Sci* 2001, 170:103–106.
203. **Heard K, Green JL, et al.** A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. *Aliment Pharmacol Ther* 2007; 26: 283–90.

204. **Heinonen S, Eloranta ML, Heiskanen J, et al.** Maternal susceptibility locus for obstetric cholestasis maps to chromosome region 2p13 in Finnish patients. *Scand J Gastroenterol* 2001; 36:766–770..
205. **Heneghan MA, Norris SM, O’Grady JG, Harrison PM, McFarlane IG.** Management and outcome of pregnancy in autoimmune hepatitis. *Gut* 2001; 48: 97–102.
206. **Hernandez LV, Gilson I, Jacobson J, et al.** Antiretroviral hepatotoxicity in uman immunodeficiency virus-infected patients. *Aliment Pharmacol Ther* 2001;15: 1627–32.
207. **Hepburn,** *Hepatology* 2008; 47:1067–76.
208. **Hieber JP, Dalton D, Shorey J, Combes B:** Hepatitis and pregnancy. *J Pediatr* 1977, 91:545–549.
209. **Hill JB, Sheffield JS, Kim MJ, et al.** Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. *Obstet Gynecol* 2002; 99: 1049–52.
210. **Hillemanns P, Dannecker C, Kimmig R, Hasbargen U:** Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy. *Acta Obstet Gynecol Scand* 2000, 79:543–547.
211. **Hirshfeld-Cytrin J, Lam C, Karumanchi SA, Lindheimer MD.** Late postpartum eclampsia: examples and review. *Obstet Gynecol Survey* 2006;61:471–80.
212. **Hladunewich M, Karumanch SA, Lafayette R.** Pathophysiology of the clinical manifestations of preeclampsia. *Clin J Am Soc Nephrol* 2007;2:543–9.
213. **Ho KM, Sheridan DJ:** Meta-analysis of frusemide to prevent or treat acute renal failure. *BMJ* 2006, 333:420.
214. **Ho“llmu” ller I, Stadlmann S, Graziadei I.** Clinico-histopathological characteristics of clopidogrel-induced hepatic injury:

- case report and review of literature. *Eur J Gastroenterol Hepatol* 2006; 18: 931–4.
215. **Hoofnagle J.H.** Drug-induced liver injury network (DILIN). *Hepatology* (2004) 40 773.
216. **Hosono M, Togashi K, Kawakami S, Itoh K, Fukuoka M, Kobayashi F, Mori T, Konishi J.** MR demonstration of reversible periportal abnormal intensity in eclampsia. *J Comput Assist Tomogr* 1994;18:143–145.
217. **Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL.** Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. *Hepatology* 1999; 30: 1312–7..
218. **Huang Y.S., Su W.J., Huang Y.H. et al.** Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1 and the susceptibility to drug-induced liver injury. *J. Hepatol.* (2007) 47 128–134..
219. **Hunt CM, Carson KL, Sharara AI:** Hepatitis C in pregnancy. *Obstet Gynecol* 1997, 89:883–890.
220. **Hupuczi P, Rigo B, Sziller I, Szabo G, Szigeti Z, Papp Z:** Follow-up analysis of pregnancies complicated by HELLP syndrome. *Fetal Diagn Ther* 2006, 21:519-522.
221. **Hussaini S.H., O'Brien C.S., Despott E.J., Dalton H.R.** Antibiotic therapy a major cause of drug-induced jaundice in southwest England. *Eur. J. Gastroenterol. Hepatol.* (2007) 19 15–20.
222. **Hussaini SH, O'Brien CS, Despott EJ, Dalton HR.** Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. *Eur J Gastroenterol Hepatol* 2007; 19: 15–20.

223. **Hutchinson SJ, Goldberg DJ, King M, et al.**: Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. *Gut* 2004, 53:593–598.
224. **Ibañez L., Peñeriz E., Vidal X., Laporte J.R.** The Grup d'Estudi Multicentric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. *J. Hepatol.* (2002) 37 592–600.
225. **Ibdah JA, Bennett MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF et al. 1999.** A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. *New England Journal of Medicine* 340:1723 – 1731.
226. **Ibdah JA, Bennett MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF, Strauss AW:** A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. *N Engl J Med* 1999, 340:1723-1731.
227. **Ijaz R, Jereb JA, Lambert LA, et al.** Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. *Clin Infect Dis* 2006; 42: 346–55.
228. **Imagawa DK, Dawson S 3rd, Holt CD, et al.** Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxyl-methylglutaryl- coenzyme A reductase inhibitor pravastatin. *Transplantation* 1996; 62: 934–42.
229. **Irgens HU, Reisaeter L, Irgens LM, Lie RT.** Long-term mortality of mothers and fathers after preeclampsia: population-based cohort study. *BMJ* 2001;323:1213–7.
230. **Isler CM, Magann EF, Rinehart BK, Terrone DA, Bass JD, Martin JN Jr:** Dexamethasone compared with betamethasone for

- glucocorticoid treatment of postpartum HELLP syndrome. *Int J Gynaecol Obstet* 2003, 80:291-297.
231. **Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, Martin JN Jr:** Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. *Am J Obstet Gynecol* 1999, 181:924-928.
 232. **Jain AB, Reyes J, Marcos A, et al.** Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. *Transplantation* 2003; 76: 827–32.
 233. **Jain MK, Parekh NK, Hester J, et al.** Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. *AIDS Patient Care STDS* 2006; 20: 817–22.
 234. **Jain MK.** Drug-induced liver injury associated with HIV medications. *Clin Liver Dis* 2007; 11: 615–39..
 235. **Jewell D & Young G.** Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev* 2003; (4): CD000145.
 236. **Jobe AH, Soll RF:** Choice and dose of corticosteroid for antenatal treatments. *Am J Obstet Gynecol* 2004, 190:878-881.
 237. **Jonas MM, Schiff ER, O'Sullivan MJ, et al.** Failure of the centers for disease control criteria to identify hepatitis B infection in a large municipal obstetrical population. *Ann Intern Med* 1987; 107: 335–7.
 238. **Jonker JW, Stedman CA, Liddle C, Downes M.** Hepatobiliary ABC transporters: physiology, regulation and implications for disease. *Front Biosci* 2009; 14:4904–4920. A review of cell and molecular mechanisms of ICP.
 239. **Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfu'sson N.** Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. *Acta Obstet Gynecol Scand* 1995;74:772–6.

240. **Kainz A, Harabacz I, Cowrick IS, Gadgil SD, Hagiwara D.** Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. *Transplantation* 2000; 70: 1718–21..
241. **Kallen B.** Use of antihistamine drugs in early pregnancy and delivery outcome. *J Matern Fetal Neonatal Med* 2002; 11(3): 146–152.
242. **Kandler C, Kevekordes B, Zenker M, Kandler M, Beinder E, Lang N, Harms D:** Prognosis of children born to mothers with HELLPsyndrome. *J Perinat Med* 1998, 26:486-490.
243. **Kandutsch S, Klinger M, Hacker S, et al.** Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. *Eur J Surg Oncol* 2008; Epub ahead of print.
244. **Kang AH, Graves CR.** Herpes simplex hepatitis in pregnancy: a case report and review of the literature. *Obstet Gynecol Surv* 1999; 54: 463–68.
245. **Kang H, Choi JD, et al.** A case of methimazole-induced acute hepatic failure in a patient with chronic hepatitis B carrier. *Korean J Intern Med* 1990; 5: 69–73.
246. **Kaplan MM. 1985. Acute fatty liver of pregnancy.** *New England Journal of Medicine* 31:367 – 370.
247. **Kaplan MM. Acute fatty liver of pregnancy.** *N Engl J Med* 1985;313:367–370..
248. **Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP:** Preeclampsia: a renal perspective. *Kidney Int* 2005, 67:2101-2113.
249. **Katz L, de Amorim MM, Figueiroa JN, JL ES:** Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial. *Am J Obstet Gynecol* 2008

[http://download.journals.elsevierhealth.com/pdfs/journals/00029378/PII_S0002937807020194.main-abr.pdf].

250. **Keeffe EB, Dieterich DT, Pawlotsky JM, et al.** Chronic hepatitis B: preventing, detecting and managing viral resistance. *Clin Gastroenterol Hepatol* 2008; 6: 268– 74..
251. **Keeffe EB, Sunderland MC, Gabourel JD.** Serum g-glutamyl transpeptidase activity in patients receiving chronic phenytoin therapy. *Dig Dis Sci* 1986;31:1056–1061.
252. **Kennedy S, Hall PM, Seymour AE, Hague WM. 1994.** Transient diabetes insipidus and acute fatty liver of pregnancy. *British Journal of Obstetrics and Gynaecology* 101:387 – 391.
253. **Kenyon A, Piercy C, Girling J, et al.** Obstetric cholestasis, outcome with active management: a series of 70 cases. *BJOG* 2002; 109:282–288.
254. **Khorashadi S, Hasson NK, Cheung RC.** Incidence of statin hepatotoxicity in patients with hepatitis C. *Clin Gastroenterol Hepatol* 2006; 4: 902–7..
255. **Khuroo MS, Datta DV.** Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. *Am J Med* 1980; 68: 113–21.
256. **Khuroo MS, Kamili S.** Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. *J Viral Hepat* 2003; 10: 61–69.
257. **Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI.** Incidence and severity of viral hepatitis in pregnancy. *Am J Med* 1981; 70: 252–55.

258. **Kim HY, Sohn YS, Lim JH, Kim EH, Kwon JY, Park YW, Kim YH:** Neonatal outcome after preterm delivery in HELLP syndrome. *Yonsei Med J* 2006, 47:393-398.
259. **Kittner SJ, Stern BJ, Feeser BR, Hebel R, Nagey DA, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Sloan MA, et al.:** Pregnancy and the risk of stroke. *N Engl J Med* 1996, 335:768-774.
260. **Kjell Haram¹, Einar Svendsen and Ulrich Abildgaard.** The HELLP syndrome: Clinical issues and management 2009.
261. **Klein NA, Mabie WC, Shaver DC, et al.** Herpes simplex virus hepatitis in pregnancy. Two patients successfully treated with acyclovir. *Gastroenterology* 1991; 100: 239–44.
262. **Knapen MF, Mulder TP, Bisseling JG, Penders RH, Peters WH, Steegers EA:** Plasma glutathione S-transferase alpha 1-1: a more sensitive marker for hepatocellular damage than serum alanine aminotransferase in hypertensive disorders of pregnancy. *Am J Obstet Gynecol* 1998, 178:161-165.
263. **Knapen MF, Mulder TP, Van RI, Peters WH, Steegers EA:** Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. *Obstet Gynecol* 1998, 92:1012-1015.
264. **Knight B, Mudge C, Openshaw S et al.** Effect of acupuncture on nausea of pregnancy: a randomized, controlled trial. *Obstet Gynecol* 2001; 97(2): 184–188.
265. **Knopp RH.** Drug treatment of lipid disorders. *N Engl J Med* 1999; 341: 498–511. 43 Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. *J Pharmacol Exp Ther* 1989; 248: 498– 505.

266. **Knowles SR, Shaprio LE, Shear NH.** Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. *Drug Saf* 1999; 21: 489–501.
267. **Knox TA, Olans LB. 1996.** Liver disease in pregnancy. *The New England Journal of Medicine* 335:569 – 576.
268. **Knox TA, Olans LB:** Liver disease in pregnancy. *N Engl J Med* 1996, 335:569-576.
269. **Ko CW, Beresford SA, Schulte SJ, Matsumoto AM, Lee SP.** Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. *Hepatology* 2005; 41: 359–65.
270. **Koenen SV, Huisjes AJ, Dings J, van der GY, Visser GH, Bruinse HW:** Is there a diurnal pattern in the clinical symptoms of HELLP syndrome? *J Matern Fetal Neonatal Med* 2006, 19:93-99.
271. **Kondrackiene J, Kupcinskas L.** Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems. *World J Gastroenterol* 2008; 14 : 5781–5788. This review identifies the many unsolved dilemmas in the management of ICP. The need for clinical trial to evaluate early delivery and the role of UDCA is emphasized.
272. **Koren G & Levichek Z.** The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. *Am J Obstet Gynecol* 2002; 186(5 Suppl Understanding): S248–S252
273. **Koren G & Maltepe C.** Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. *J Obstet Gynaecol* 2004; 24(5): 530–533.
274. **Kottiril S, Jagannatha S, Lu A, et al.:** Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. *HIV Clin Trials* 2004, 5:25–32.

275. **Kuffner EK, Dart RC , Bogdan GM, et al.** Effect of maximum daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med* 2001; 161: 2247–52.
276. **Kumar RM, Shahul S:** Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. *J Hepatol* 1998, 29:191–197.
277. **Kumar RM, Uduman S, Rana S, Kochiyil JK, Usmani A, Thomas L.** Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. *Eur J Obstet Gynecol Reprod Biol* 2001; 100: 9–15.
278. **Kurihara T, Akimoto M, Abe K, et al.** Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. *Clin Ther* 1993; 15: 890–8.
279. **La Torre A, Biadaoli R, Capobianco T, et al.:** Vertical transmission of HCV. *Acta Obstet Gynecol Scand* 1998, 77:889–892.
280. **Laffi G, Lavilla G, Pinzani M, et al.** Arachidonic acid derivatives and renal function in liver cirrhosis. *Semin Nephrol* 1997; 17: 530–48.
281. **Lagiou P, Tamimi R, Mucci LA et al.** Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. *Obstet Gynecol* 2003; 101(4): 639–6344.
282. **Lamer P:** Current controversies surrounding the use of repeated courses of antenatal steroids. *Adv Neonatal Care* 2002, 2:290-300.
283. **Lanhard MJ, Funk WB.** Failure to develop hepatic injury from rosiglitazone in a patient with history of troglitazone-induced hepatitis. *Diabetes Care* 2001; 24: 168–9.
284. **Larson AM, Polson J, Fontana RJ, et al.** Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. *Hepatology* 2005; 42: 1364–72.

285. **Latt NC, Spencer JD, Beeby PJ, et al.**: Hepatitis C in injecting drug-using women during and after pregnancy. *J Gastroenterol Hepatol* 2000, 15:175–181.
286. **Lau WY, Leung WT, Ho S, et al.** Hepatocellular carcinoma during pregnancy and its comparison with other pregnancy-associated malignancies. *Cancer* 1995; 75: 2669–76.
287. **Le Thi TD, Tieulie N, Costedoat N, Andreu MR, Wechsler B, Vauthier-Brouzes D, Aumaitre O, Piette JC**: The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. *Ann Rheum Dis* 2005, 64:273-278.
288. **Lebovitz HE, Kreider M, Freed MI.** Evaluation of liver function in Type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. *Diabetes Care* 2002; 25:815–21.
289. **Lee AK, Ip HM, Wong VC.** Mechanisms of maternal–fetal transmission of hepatitis B virus. *J Infect Dis* 1978; 138: 668–71.
290. **Lee C, Gong Y, Brok J, Boxall EH, Gluud C.** Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and metaanalysis. *BMJ* 2006; 332: 328–36.
291. **Lee R, Incerpi M, Miller D, et al.** Sudden fetal death in intrahepatic cholestasis of pregnancy. *Obstet Gynecol* 2009; 113 (2, Part 2):528–531. This is a case report of sudden fetal death despite normal antepartum testing. One case is preterm at 32 weeks' gestation with severe ICP.
292. **Lee RH, Goodwin TM, Greenspoon J, et al.** The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. *J Perinatol* 2006; 26:527–532.

293. **Lee RH, Kwok KM, Ingles S, et al.** Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. *Am J Perinatol* 2008; 25:341–345. This is a retrospective review showing no increase in maternal or fetal morbidity and mortality using early induction at 37 weeks' gestation.
294. **Lee S-D, Tsai K-S, Wu T-C, et al.** Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. *Lancet* 1988; 2: 833–4.. .
295. **Lee WM, Squires RH Jr, Nyberg SL, et al.** *Acute liver failure: summary of a workshop.* *Hepatology* 2008; 47: 1401–15. 31
296. **Lees C, Langford E, Brown AS, de BA, Pickles A, Martin JF, Campbell S:** The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. *Obstet Gynecol* 1996, 88:14-19.
297. **Levy C, Seef LD, Lindor KD.** Use of herbal supplements for chronic liver disease. *Clin Gastroenterol Hepatol* 2004; 2: 947–56.
298. **Levy M, Koren G.** Hepatitis B vaccine in pregnancy: maternal and fetal safety. *Am J Perinatol* 1991; 8: 227–32. .
299. **Lewis JH, Kleiner D.** Hepatic Injury due to drugs, chemicals and toxins. In: Burt AD, Portman B, Ferrel LD, eds. *Macswen's Pathology of the Liver*, 5th edn. Oxford: Churchill Livingstone, 2007: 659– 752.
300. **Lewis JH, Mortensen ME, Zweig S, et al.** Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double- blind, placebo-controlled, multicenter trial. *Hepatology* 2007; 46: 1453–63.

301. **Lewis JH, Schiff ER.** Methotrexate-induced chronic liver injury: guidelines for detection and prevention. *Am J Gastroenterol* 1998; 88: 1137–345.
302. **Lewis JH.** *Licorice for hepatitis C*: yumyum or just ho-hum? *Am J Gastroenterol* 2001; 96: 2291–2.
303. **Lewis JH.** Liver disease caused by anesthetics, toxins and herbal preparations. In: Feldman M, Friedman LJ, Brandt LJ, eds. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*, 8th edn. Philadelphia, PA, USA: Saunders, 2006: 1853–68.
304. **Lewis JH.** Monitoring for methotrexate hepatotoxicity in patients with rheumatoid arthritis: another hepatologist's perspective. *J Rheumatol* 1997; 24:1459–60.
305. **Lewis JH.** *NSAID-induced hepatotoxicity*. *Clin Liver Dis* 1998; 2: 543–61.
306. **Li X-M, Shi M-F, Yang Y-B, et al.** Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection.
307. **Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, et al.** Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. *Hypertension* 2007;50:686–92.
308. **like retinopathy in a patient with HELLP syndrome.** *Am J Ophthalmol* 2007, 143:886-887.
309. **Lim W, Eikelboom JW, Ginsberg JS.** Inherited thrombophilia and pregnancy associated venous thromboembolism. *BMJ* 2007; 334: 1318–21.
310. **Lin HH, Chen PJ, Chen DS, et al.** Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. *J Med Virol* 1989; 29: 1–6.

311. **Lin HH, Kao JH, Hsu HY, et al.** Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. *J Pediatr* 1995; 126:589–591.
312. **Lin HH, Lee TY, Chen DS, et al.** Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. *J Pediatr* 1987; 111: 877–81.
313. **Lin HH, Wu WY, Kao JH, et al.** Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. *J Gastroenterol Hepatol* 2006; 21: 605–9.
314. **Lindheimer M, Richardson DA, Ehrlich EN, Katz AI.** Potassium homeostasis in pregnancy. *J Reprod Med* 1987;32:517–22..
315. **Lindheimer MD, Umans JG.** Explaining and predicting preeclampsia (editorial). *N Engl J Med* 2006;355:1056–8.
316. **Lindseth G, Bird-Baker MY.** Risk factors for cholelithiasis in pregnancy. *Res Nurs Health* 2004; 27: 382–91.
317. **Lonergan JT, Behling C, et al.** Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. *Clin Infect Dis* 2000; 31: 162–6.
318. **Lowenthal KE, Horn PJ, et al.** Concurrent use of methotrexate and acitretin revisited. *J Dermatol Treat* 2008; 19: 22–6.
319. **Lucangioli SE, Castan˜o G, Contin MD, et al.** Lithocholic acid as a biomarker of intrahepatic cholestasis of pregnancy during ursodeoxycholic acid treatment. *Ann Clin Biochem* 2009; 46 (1):44–49..
320. **Lucena M.I., Andrade R.J., Rodrigo L. et al.** Trovafloxacin-induced acute hepatitis. *Clin. Infect. Dis.* (2000) 30 400–401.

321. **Ma Isabel Lucenaa, Miren Garcí'a-Corte'sb.** Assessment of drug induced liver injury in clinical practice 2008.
322. **MacLean MA, Cameron AD, Cumming GP, Murphy K, Mills P, Hilan KJ. 1994.** Recurrence of acute fatty liver of pregnancy. *British Journal of Obstetrics and Gynaecology* 101: 453 – 454.
323. **Magann EF, Graves GR, Roberts WE, Blake PG, Morrison JC, Martin JN Jr:** Corticosteroids for enhanced fetal lung maturation in patients with HELLP syndrome: impact on neonates. *Aust N Z J Obstet Gynaecol* 1993, 33:131-135. 121. Magann EF, Martin JN Jr: Critical care of HELLP syndrome with corticosteroids. *Am J Perinatol* 2000, 17:417-422.
324. **Magann EF, Martin JN Jr:** Twelve steps to optimal management of HELLP syndrome. *Clin Obstet Gynecol* 1999, 42:532-550.
325. **Magann EF, Perry KG Jr, Meydrech EF, Harris RL, Chauhan SP, Martin JN Jr:** Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). *Am J Obstet Gynecol* 1994, 171:1154-1158..
326. **Magee LA, Mazzotta P & Koren G.** Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). *Am J Obstet Gynecol* 2002; 186(5 Suppl Understanding): S256–S261.
327. **Magee LA, Miremadi S, Li J, Ensom MH, Carleton B, Co'te' AM, et al.** Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. *Am J Obstet Gynecol* 2005;193:153–63.
328. **Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, Sagara Y, Kajiwarra Y, Urata M:** Antithrombin therapy for severe preeclampsia: results of a double-blind,

- randomized, placebo-controlled trial. BI51.017 Study Group. *Thromb Haemost* 2000, 84:583-590.
329. **Mallal S, Nolan D, Witt C, et al.** Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. *Lancet* 2002; 359: 727–32.
330. **Mangione S, Giaratano A:** The role of antithrombin III in critical patients in obstetrics. *Minerva Anesthesiol* 2002, 68:449-453.
331. **Manolio TA, Burke GL, Savage PJ, Jacobs DR Jr, Sidney S, Wagenknecht LE, Allman RM, Tracy RP.** Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. *Clin Chem* 1992;38: 1853–1859.
332. **Marchand A, Galen RS, Van LF:** The predictive value of serum haptoglobin in hemolytic disease. *JAMA* 1980, 243:1909-1911.
333. **Marchesini G, Brizi M, Bianchi G, et al.** Metformin in nonalcoholic steatohepatitis. *Lancet* 2001; 358: 893–4..
334. **Marshall D. Lindheimer, MDa, Sandra J. Taler, MD.** Hypertension in pregnancy 2010.
335. **Martagon J, Gordon SM:** Special management challenges in hepatitis C. *Cleve Clin J Med* 2003, 70(Suppl 4):S27–S33.
336. **Martin AM, Nolan D, James I, et al.** Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. *AIDS* 2005; 19: 97–9.
337. **Martin JN Jr, Blake PG, Lowry SL, Perry KG Jr, Files JC, Morrison JC:** Pregnancy complicated by preeclampsia-eclampsia with the syndrome of hemolysis, elevated liver enzymes, and low platelet count: how rapid is postpartum recovery? *Obstet Gynecol* 1990, 76:737-741.

338. **Martin JN Jr, Blake PG, Perry KG Jr, McCaul JF, Hess LW, Martin RW:** The natural history of HELLP syndrome: patterns of disease progression and regression. *Am J Obstet Gynecol* 1991, 164:1500-1509.
339. **Martin JN Jr, Files JC, Blake PG, Norman PH, Martin RW, Hess LW, Morrison JC, Wiser WL:** Plasma exchange for preeclampsia. I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. *Am J Obstet Gynecol* 1990, 162:126-137.
340. **Martin JN Jr, Files JC, Blake PG, Perry KG Jr, Morrison JC, Norman PH.** Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. *Am J Obstet Gynecol* 1995;172(4 Part 1):1107-1125.
341. **Martin JN Jr, Perry KG Jr, Blake PG, May WA, Moore A, Robinette L:** Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. *Am J Obstet Gynecol* 1997, 177:1011-1017.
342. **Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG:** *The spectrum of severe preeclampsia:* comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. *Am J Obstet Gynecol* 1999, 180:1373-1384.
343. **Martin JN Jr, Rose CH, Briery CM:** Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. *Am J Obstet Gynecol* 2006, 195:914-934.
344. **Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W.** Stroke and severe preeclampsia, and eclampsia: a paradigm

- shift focusing on systolic blood pressure. *Obstet Gynecol* 2005;246–54.
345. **Martin JN Jr, Thigpen BD, Rose CH, Cushman J, Moore A, May WL:** Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. *Am J Obstet Gynecol* 2003;189:830–834.
346. **Matchaba P, Moodley J:** Corticosteroids for HELLP syndrome in pregnancy. *Cochrane Database Syst Rev* 2004;CD002076. 123. Magann EF, Bass D, Chauhan SP, Sullivan DL, Martin RW, Martin JN Jr: Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). *Am J Obstet Gynecol* 1994, 171:1148–1153.
347. **Matsuda M, Mitsuhashi S, Watarai M, Yamamoto K, Hashimoto T, Ikeda S:** Hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome associated with systemic lupus erythematosus. *Intern Med* 2003, 42:1052–1053.
348. **Mattar F, Sibai BM. Eclampsia. VIII.** Risk factors for maternal morbidity. *Am J Obstet Gynecol* 2000;182: 307–12.
349. **Mayer SA, Aledort LM:** Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies. *Mt Sinai J Med* 2005, 72:166–175.
350. **Maynard S, Epstein FH, Karumanchi SA.** Preeclampsia and angiogenic imbalance. *Ann Rev Med* 2007;59:61–78.
351. **Mays JK, Fuks A. M. Otuyelu-Garritano, et al.** Abstract: Meconium-stained amniotic fluid in patients with intrahepatic cholestasis of pregnancy. *Obstet Gynecol* 2007; 109:86S.
352. **Mazzotta P & Magee LA.** A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. *Drugs* 2000; 59(4): 781–800.

353. **McGovern BH, Birch C, Zaman MT, et al.** Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon. *Clin Infect Dis* 2007; 45: 1386–92.
354. **McMahon MA, Jilek BL, Brennan TP, et al.** The HBV drug entecavir – effects on HIV-1 replications and resistance. *N Engl J Med* 2007; 356: 2614–21.
355. **McMaster MT, Zhou Y, Fisher SJ.** Abnormal placentation and the syndrome of preeclampsia. *Semin Nephrol* 2004;24:540–7.
356. **Meier Y., Cavallaro M., Roos M. et al.** Incidence of drug-induced liver injury in medical inpatients. *Eur. J. Clin. Pharmacol.* (2005) 61 135–143.
357. **Mele A, Tancredi F, Romano L, et al.** Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigenpositive mothers in Italy. *J Infect Dis* 2001; 184: 905–8.
358. **Mendez-Sanchez N, Chavez-Tapia NC, Uribe M.** Pregnancy and gallbladder disease. *Ann Hepatol* 2006; 5: 227–30.
359. **Mendis GP, Gibberd FB, Hunt HA.** Plasma activities of hepatic enzymes in patients on anticonvulsant therapy. *Seizure* 1993;2:319–323.
360. **Mendis GP, Gibberd FB, Hunt HA.** Plasma activities of hepatic enzymes in patients on anticonvulsant therapy. *Seizure* 1993;2:319–323.
361. **Menzies J, Magee LA, MacNab YC, Ansermino JM, Li J, Douglas MJ, et al.** Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. *Hypertens Pregnancy* 2007;26:447–62.
362. **Merchant SH, Mathew P, Vanderjagt TJ, Howdieshell TR, Crookston KP:** Recombinant factor VIIa in management of

- spontaneous subcapsular liver hematoma associated with pregnancy. *Obstet Gynecol* 2004, 103:1055-1058.
363. **Michael P. Manns, Albert J. Czaja, James D. Gorham, Edward L. Krawitt, Giorgina Mieli-Vergani, Diego Vergani, and John M. Vierling.** *Diagnosis and Management of Autoimmune Hepatitis* 2007.
 364. **Mihu D, Costin N, Mihu CM, Seicean A, Ciortea R:** HELLP syndrome – a multisystemic disorder. *J Gastrointestin Liver Dis* 2007, 16:419-424.
 365. **Miller KD, Cameron M, Wood LV, et al.** Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. *Ann Intern Med* 2000; 133: 192–6.
 366. **Minakami H, Oka N, Sato T et al.** Preeclampsia: a microvesicular fat disease of the liver? *Am J Obstet Gynecol* 1988;159:1043–7.
 367. **Minakami H, Takahashi T, Tamada T. 1991.** Should routine liver biopsy be done for the definite diagnosis of acute fatty liver of pregnancy? *American Journal of Obstetrics and Gynecology* 164:1690 – 1691.
 368. **Minakami H, Yamada H, Suzuki S.** Gestational thrombocytopenia and pregnancy-induced antithrombin deficiency: progenitors to the development of the HELLP syndrome and acute fatty liver of pregnancy. *Semin Thromb Hemost* 2002;28:515–8.
 369. **Minuk G.** Canadian Association of Gastroenterology Practice Guidelines: evaluation of abnormal liver enzyme tests. *Can J Gastroenterol* 1998;12:417–421.
 370. **Mira JA, Macias J, Giron-Gonzalez JA, et al.** Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. *J Antimicrob Chemother* 2006; 58: 140–6.

371. **Mok MY, Ng WL, et al.** Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. *Clin Exp Rheumatol* 2000; 18: 363–8.
372. **Moldenhauer JS, O'Brein JM, Barton JR, Sibai B. 2004.** Acute fatty liver of pregnancy associated with pancreatitis: A life threatening complication. *American Journal of Obstetrics and Gynecology* 190:502 – 505.
373. **Molokhia M., McKeigue P.** EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics* (2006) 7 633–638.
374. **Moutquin JM, Garner PR, Burrows RF, Rey E, Helewa ME, Lange IR, et al.** Report of the Canadian Hypertension Society Consensus Conference 2. Non-- pharmacologic management and prevention of hypertensive disorders of Pregnancy. *CMAJ* 1997;157:907–19.
375. **Murphy MA, Ayazifar M:** Permanent visual deficits secondary to the HELLP syndrome. *J Neuroophthalmol* 2005, 25:122-127.
376. **Murray D, O'Riordan M, Geary M, Phillips R, Clarke T, McKenna P:** The HELLP syndrome: maternal and perinatal outcome. *Ir Med J* 2001, 94:16-18.
377. **Mushahwar IK.** Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. *J Med Virol* 2008; 80: 646–58.
378. **Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V.** Pregnancy outcome in liver transplant recipients. *Obstet Gynecol* 2003; 102: 121–28.

379. **Naranjo C.A., Busto U., Sellers E.M. et al.** A method for estimating the probability of adverse drug reactions. *Clin. Pharmacol. Ther.* (1981) 30 239–245.
380. **National Institutes of Health:** Consensus Development Conference Statement: Management of hepatitis C: 2002, June 10-12, 2002. *Hepatology* 2002, 36:S3–S20.
381. **Navaneethan U, Al MM, Shata MT.** Hepatitis E and pregnancy: understanding the pathogenesis. *Liver Int* 2008; 28: 1190–99
382. **Nelson KB, Grether JK:** Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? *Pediatrics* 1995, 95:263-269.
383. **Nelson-Piercy C, Fayers P & de Swiet M.** Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum. *Br J Obstet Gynaecol* 2001; 108(1): 9–15.
384. **Nelson-Piercy C.** Treatment of nausea and vomiting in pregnancy. When should it be treated and what can be safely taken? *Drug Saf* 1998; 19(2): 155–164.
385. **Neuschwander-Tetri BA, Brunt EM, et al.** Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology* 2003; 38: 1008–17.
386. **Newell ML, Pembrey L:** Mother-to-child transmission of hepatitis C virus infection. *Drugs Today (Barc)* 2002, 38:321–337.
387. **Nimmaanrat S, Prechawai C, Tanomkiat W.** Anesthetic techniques and complications in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection. *Minerva Anesthesiol* 2007; 73: 333–7.
388. **Nourja P, Willey M.** Epidemiology of acetaminophen-related overdose. Department of Health and Human Services, Center for Drug

- Evaluation and Research, Food and Drug Administration (FDA), 2002. Available at: <http://www.fda.gov/> (accessed February 2007).
389. **Novak D, Lewis JH.** Drug-induced liver disease. *Curr Opin Gastro* 2003; 19: 203–15.
390. **Nunez M, Lana R, Mendoza JL, et al.** Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2001; 27: 426–31.
391. **Nunez M, Soriano V.** Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. *Drug Saf* 2005; 28:53–66.
392. **O'Donohue J, Oien KA, Donaldson P, et al.** Co-amoxiclav jaundice: clinical and histological features and HLA class II associations. *Gut* 2000; 47: 717–20.
393. **O'Brien JM, Barton JR:** Controversies with the diagnosis and management of HELLP syndrome. *Clin Obstet Gynecol* 2005, 48:460-477.
394. **O'Brien JM, Shumate SA, Satchwell SL, Milligan DA, Barton JR:** Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. *Am J Obstet Gynecol* 2002, 186:475-479.
395. **Ogedegbe AE, Thomas DL, Diehl AM.** Hyperlactataemia syndromes associated with HIV therapy. *Lancet Infect Dis* 2003; 3: 329–37.
396. **Oketani M, Shibatou T, Yamashita K, Arima T:** Postpartum acute exacerbation of chronic hepatitis C with complete response to interferon-alpha. *J Gastroenterol* 2002, 37:658–662.
397. **O'Shea TM, Doyle LW:** Perinatal glucocorticoid therapy and neurodevelopmental outcome: an epidemiologic perspective. *Semin Neonatol* 2001, 6:293-307.

398. **Osmanagaoglu MA, Erdogan I, Zengin U, Bozkaya H:** Comparison between HELLP syndrome, chronic hypertension, and superimposed preeclampsia on chronic hypertension without HELLP syndrome. *J Perinat Med* 2004, 32:481-485.
399. **Osmanagaoglu MA, Osmanagaoglu S, Ulusoy H, Bozkaya H:** Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital. *Sao Paulo Med J* 2006, 124:85-89.
400. **Otuyelu-Garritano KO, Demasio K, Fuks A. et al.** Abstract: effects of meconium and elevated transaminases on neonatal outcome in cholestasis of pregnancy. *Obstet Gynecol* 2007; 109: 120S.
401. **Outlaw WM & Ibdah JA.** Impaired fatty acid oxidation as a cause of liver disease associated with hyperemesis gravidarum. *Med Hypotheses* 2005; 65(6): 1150–1153.
402. **Oviedo J, Wolfe MM.** Alcohol acetaminophen, and toxic effects on the liver. *Arch Intern Med* 2002; 162: 1193.
403. **Ozer J, Ratner M, et al.** The current state of serum biomarkers of hepatotoxicity. *Toxicology* 2008; 245: 194–205
404. **Oztekin D, Aydal I, Oztekin O, et al.** Predicting fetal asphyxia in intrahepatic cholestasis of pregnancy. *Arch Gynecol Obstet* 2009; 280:975–979. This study shows an association between exposure time to elevated bile acids and asphyxia.
405. **Padden MO: HELLP syndrome:** recognition and perinatal management. *Am Fam Physician* 1999, 60:829-838.
406. **Page EW, Christianson RE.** The mean impact of mean arterial pressure in the middle trimester on the outcome of pregnancy. *Am J Obstet Gynecol* 1976;125:740–6..
407. **Palmon R, Koo BC, Shoultz DA, et al.** Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2002; 29: 340–5.

408. **Pappalardo BL:** Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. *Int J Epidemiol* 2003, 32:727–734.
409. **Paredes AH, Lewis JH.** Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. *Ann Pharmacother* 2007; 41: 880–4.
410. **Parnas M, Sheiner E, Shoham-Vardi I, Burstein E, Yermiahui T, Levi I, Holcberg G, Yerushalmi R:** Moderate to severe thrombocytopenia during pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2006, 128:163-168.
411. **Paruk F, Moodley J:** Maternal and neonatal outcome in early and late-onset pre-eclampsia. *Semin Neonatol* 2000, 5:197-207..
412. **Paternoster DM, Stella A, Simioni P, Mussap M, Plebani M:** Coagulation and plasma fibronectin parameters in HELLP syndrome. *Int J Gynaecol Obstet* 1995, 50:263-268.
413. **Pauli-Magnus C., Meier P.J.** Hepatobiliary transporters and drug-induced cholestasis. *Hepatology* (2006) 4 778–787.
414. **Pauzner R, Dulitzky M, Carp H, Mayan H, Kenett R, Farfel Z, Many A:** Hepatic infarctions during pregnancy are associated with the antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome. *J Thromb Haemost* 2003, 1:1758-1763..
415. **Peeters A, Van de Wyngaert F, Van Lierde M et al.** Wernicke's encephalopathy and central pontine myelinolysis induced by hyperemesis gravidarum. *Acta Neurol Belg* 1993; 93(5): 276–282.
416. **Peire M.A., Lucena M.I., Ruiz-Extremera A., Jara P., Romero-Gonzalez J., Andrade R.J.** Drug-induced hepatotoxicity in children. Where we are and where we are going. *An. Esp. Pediatr.* (2002) 56 433–442.

417. **Perez Gutthann S., Garcia Rodriguez L.A.** The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. *Epidemiology* (1993) 4 496–501.
418. **Perez-Cerda C, Merinero B, Jimenez A, Garcia MJ, Sanz P, Ijlst L et al.** 1993. First report of prenatal diagnosis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency in a pregnancy at risk. *Prenatal Diagnosis* 13:529 – 533.
419. **Pfeffer MA, Keech A, Sacks FM, et al.** Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. *Circulation* 2002; 105: 2341–6. 26 Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. *Clin Liver Dis* 2003; 7: 415–33.
420. **Physicians' Desk Reference, 62nd edn.** Montvale, NJ, USA: Medical Economics Company, Inc., 2008.
421. **Pinna AD, Rakela J, Demetris AJ, Fung JJ.** Five cases of fulminant hepatitis due to herpes simplex virus in adults. *Dig Dis Sci* 2002; 47: 750–54.
422. **Pliego Perez AR, Zavala Soto JO, Rodriguez BR, Martinez Herrera FJ, Porras JA:** Spontaneous hepatic rupture of pregnancy. A report of four cases and medical literature review. *Ginecol Obstet Mex* 2006, 74:224-231.
423. **Pockros PJ, Peters RL, Reynolds TB.** 1984. Idiopathic fatty liver of pregnancy. Findings in ten cases. *Medicine* 63:1 – 1.
424. **Podesta A, Lopez P, Terg R, et al.** Treatment of pruritus of primary biliary cirrhosis with rifampin. *Dig Dis Sci* 1991; 36: 216–20.
425. **Podymow T, August P, Umans JG.** Antihypertensive therapy in pregnancy. *Semin Nephrol* 2004;24:616–25.
426. **Poldre PA:** Haptoglobin helps diagnose the HELLP syndrome. *Am J Obstet Gynecol* 1987, 157:1267.

427. **Polson JE.** Hepatotoxicity due to antibiotics. *Clin Liver Dis* 2007; 11: 549–61.
428. **Poole JH:** Aggressive management of HELLP syndrome and eclampsia. *AACN Clin Issues* 1997, 8:524-538.
429. **Poston L, Briley A, Seed P, Kelly F, Shennan A; Vitamins in Pre-eclampsia (VIP) Trial Consortium.** Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. *Lancet* 2006;367:1145–54.
430. **Poupon R, Chretien Y, Chazouilleres O, Poupon RE.** Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. *J Hepatol* 2005; 42: 418–19.
431. **Powell K, Kerkerling KW, Barker G, Rozycki HJ:** Dexamethasone dosing, mechanical ventilation and the risk of cerebral palsy. *J Matern Fetal Neonatal Med* 2006, 19:43-48.117. Vincer MJ, Allen AC, Joseph KS, Stinson DA, Scott H, Wood E: Increasing prevalence of cerebral palsy among very preterm infants: a population-based study. *Pediatrics* 2006, 118:e1621-e1626.
432. **Pradumna Jamtute, Amir Ahmad, Tarun Ghosh, & Philip Banfield.** The journal of maternal-fetal and Neonatal Medicine, Marsh 2009; 22(3): 274-283.
433. **Pratt DS, Kaplan MM.** Evaluation of abnormal liver enzyme results in asymptomatic patients. *N Engl J Med* 2000;342: 1266–1271.
434. **Pratt DS, Kaplan MM. Laboratory tests.** In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver. 8th ed, Vol. 1. Philadelphia: Lippencott-Raven; 1999.pp 205–244.
435. **Pridjian G, Puschett JB: Preeclampsia. Part 1:** clinical and pathophysiologic considerations. *Obstet Gynecol Surv* 2002, 57:598-618.

436. **Prince MI, Burt AD, Jones DE.** Hepatitis and liver dysfunction with rifampicin therapy for pruritis in primary biliary cirrhosis. *Gut* 2002; 50: 436–9.
437. **Pritchard JA, Weisman R Jr, Ratnoff OD, Vosburgh GJ:** Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. *N Engl J Med* 1954, 250:89-98.
438. **Promrat K, Lutchman G, Uwaifo GI, et al.** A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. *Hepatology* 2004; 39: 188–96.
439. **Pu YS, LIU CM, et al.** Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. *Eur Urol* 1999; 36: 293–7.
440. **Quinn PG, Johnston DE.** Detection of chronic liver disease: costs and benefits. *Gastroenterologist* 1997;5:58–77.
441. **Qureshi NS, Tomlinson AJ:** Prenatal corticosteroid therapy for elevated liver enzyme/low platelet count syndrome: a case report. *J Reprod Med* 2005, 50:64-66.
442. **Rahman TM, Wendon J.** Severe hepatic dysfunction in pregnancy. *Q J Med* 2002;95:343–357.
443. **Rallidis LS, Drakoulis CK, Parasi AS.** Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. *Atherosclerosis* 2004; 174: 193–6.
444. **Rambaldi A, Gluud C.** Propylthiouracil for alcoholic liver disease. *Cochrane Database Syst Rev* 2005; 4: CD002800.
445. **Rath W, Faridi A, Dudenhausen JW:** HELLP syndrome. *J Perinat Med* 2000, 28:249-260.
446. **Rautou PE, Plessier A, Bernuau J, Denninger MH, Moucari R, Valla D.** Pregnancy: a risk factor for Budd-Chiari syndrome? *Gut* 2009; 58: 606–08.

447. **Raval DS, Co S, Reid MA, Pildes R:** Maternal and neonatal outcome of pregnancies complicated with maternal HELLP syndrome. *J Perinatol* 1997, 17:266-269.
448. **Redman CW, Bonnar J, Beilin L:** Early platelet consumption in pre-eclampsia. *Br Med J* 1978, 1:467-469.
449. **Resti M, Azzari C, Galli L, et al.:** Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. *J Infect Dis* 2002, 185:567–572.
450. **Resti M, Azzari C, Moriondo M, et al.:** Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells. *Clin Infect Dis* 2002, 35:236–239.
451. **Reyes H, Sandoval L, Wainstein A, Ribalta J, Donoso S, Smok G et al.** 1994. Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. *Gut* 35:101 – 106..
452. **Reyes H.** The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. *Gastroenterol Clin North Am* 1992;21:905–921.
453. **Riely CA, Latham PS, Romero R, Duffy TP. 1987.** Acute fatty liver of pregnancy. A reassessment based on observations in nine patients. *Annals of Internal Medicine* 106: 703 – 706.
454. **Riley TR, Smith JP.** Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. *Am J Gastroenterol* 1998; 93: 1563–5.
455. **Rinehart BK, Terrone DA, Magann EF, Martin RW, May WL, Martin JN Jr:** Preeclampsia-associated hepatic hemorrhage and rupture: mode of management related to maternal and perinatal outcome. *Obstet Gynecol Surv* 1999, 54:196-202..

456. **Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadan G.** Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. *J Hepatol* 2002; 36: 454–8.
457. **Roberts D, Dalziel S:** Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2006, 3:CD004454.
458. **Roberts EA, Yeung L:** Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 2002, 36(Suppl 1):S106–S113.
459. **Roberts WC.** Safety of fenofibrate – US and worldwide experience. *Cardiology* 1989; 79: 169–79. .
460. **Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I:** hepatocellular injury. *Clin Liver Dis* 2007; 11: 641–62.
461. **Rodriguez-Frias EA, Lee WM. Cancer chemotherapy II:** hepatocellular injury. *Clin Liver Dis* 2007; 11: 663–76.
462. **Roelofsen AC, van Pampus MG, Aarnoudse JG:** The HELLP-syndrome; maternal-fetal outcome and follow up of infants. *J Perinat Med* 2003, 31:201-208.
463. **Rolfes DB, Ishak KG.** Liver disease in pregnancy. *Histopathology* 1986; 10: 555–70.
464. **Roncaglia N, Arreghini A, Locatelli A, et al.** Obstetric cholestasis: outcome with active management. *Eur J Obstet Gynecol Repro Biol* 2002; 100:167–170.
465. **Rose CH, Thigpen BD, Bofill JA, Cushman J, May WL, Martin JN Jr:** Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. *Obstet Gynecol* 2004, 104:1011-1014. 127. Vigil-De GP, Garcia-Caceres E: Dexamethasone in the post-partum treatment of HELLP syndrome. *Int J Gynaecol Obstet* 1997, 59:217-221..

466. **Rotger M, Colombo S, Furrer H, et al.** Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and / or nevirapine in HIV-infected patients. *Pharmacogenet Genomics* 2005; 15: 1–5.
467. **Roux CH, Brocq O, et al.** Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. *Rheumatology* 2006; 45: 1294–7.
468. **Roy B, Chowdhury A, Kundu S, et al.** Increased risk of antituberculosis druginduced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. *J Gastroenterol Hepatol* 2001; 16: 1033–7.
469. **Roy PD, Majumder M, et al.** Pharmacigenomics of anti-TB drugs-related hepatotoxicity. *Pharmacogenomics* 2008; 9: 311–21.
470. **Ruiz-Extremera A, Salmeron J, Torres C, et al.:** Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. *Pediatr Infect Dis J* 2000, 19:511–516.
471. **Rumbold A, Crowther C, Haslam R, Dekker G, Robinson J.** Vitamins C and E and the risks of preeclampsia and perinatal complications. *N Engl J Med* 2006;354:1796–806.
472. **Russell MA, Craigo SD.** Cirrhosis and portal hypertension in pregnancy. *Semin Perinatol* 1998; 22: 156–65.
473. **Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P.** Liver transplantation for acute liver failure from drug induced liver injury in the United States. *Liver Transpl* 2004; 10: 1018–23..
474. **Russo W.M., Watkins P.B.** Are Patients With Elevated Liver Tests at Increased Risk of Drug-Induced Liver Injury? *Gastroenterology* (2004) 126 1477–1480.

475. *Söderström A, Norkrans G, Lindh M.* Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. *Scand J Infect Dis* 2003; 35: 814–9.
476. *Safari HR, Fassett MJ, Souter IC et al.* The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. *Am J Obstet Gynecol* 1998; 179(4): 921–924.
477. *Saigal S, Agarwal SR, Nandeesh HP, et al.* Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. *J Gastroenterol Hepatol* 2001; 16: 1028–32.
478. *Saleh M, Abdo K.* Intrahepatic cholestasis of pregnancy: review of the literature and evaluation of current evidence. *Journal of Women's Health* 2007; 16 6..
479. *Sanne I, Mommeja-Marin H, Hinkle J, et al.* Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. *J Infect Dis* 2005; 191: 825–9.
480. *Santiago-Munoz P, Roberts S, Sheffield J, McElwee B, Wendel JGD.* Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. *Am J Obstet Gynecol* 2005; 193(Suppl. 1): 1270–3.
481. *Sato C, Nakano M, Lieber CS.* Prevention of acetaminophen induced hepatotoxicity by acute ethanol administration in the rat: comparison with carbon tetrachloride- induced hepatotoxicity. *J Pharmacol Exp Ther* 1981; 218: 805–10.
482. *Saukkonen JJ, Cohn DL, Jasmer RM, et al.* An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med* 2006; 174: 935– 52.

483. **Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P:** Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. *JAMA* 1996; 276:1805-1810.
484. **Scheuer PJ, Summerfield JA, Lal S, Sherlock S.** Rifampicin hepatitis. A clinical and histological study. *Lancet* 1974; 1: 421–5.
485. **Schiff E, Friedman SA, Kao L, Sibai BM.** The importance of urinary protein excretion during conservative management of severe preeclampsia. *Am J Obstet Gynecol* 1996;175:1313–6.
486. **Schiff MA, Reed SD & Daling JR.** The sex ratio of pregnancies complicated by hospitalisation for hyperemesis gravidarum. *Br J Obstet Gynaecol* 2004; 111(1): 27–30.
487. **Schoepfer AM, Engel A, Fattinger K, et al.** Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. *J Hepatol* 2007; 47: 521–6.
488. **Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW.** Pregnancy in autoimmune hepatitis: outcome and risk factors. *Am J Gastroenterol* 2006; 101: 556–60.
489. **Seeff LB, Curto TM, Szabo G, et al.** Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. *Hepatology* 2008; 47: 605–12.
490. **Seeff LB.** Herbal Hepatotoxicity. *Clin Liver Dis* 2007; 11: 577–96.
491. **Seifert CF, Anderson DC.** Acetaminophen usage patterns and concentrations of glutathione and gamma-glutamyl transferase in alcoholic subjects. *Pharmacotherapy* 2007; 27: 1473–82.
492. **Sentilhes L, Verspyck E, Pia P, et al.** Fetal death in a patient with intrahepatic cholestasis of pregnancy. *Obstet Gynecol* 2006; 107 (2pt 2):458–460.

493. **Sepulveda WH, Gonzales C, Cruz MA, et al.** Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. *Eur J Obstet Gynecol Repro Biol* 1991; 42:211–215.
494. **Sgro C., Clinard F., Ouazir K. et al.** Incidence of drug-induced hepatic injuries:a French population-based study. *Hepatology* (2002) 36 451–455..
495. **Sheehan H, Lynch J.** *Pathology of Toxaemia of Pregnancy*. Edinburgh: Churchill Livingstone, 1973.
496. **Sheehan HL, Lynch JP.** The pathology of toxemia. Baltimore, Maryland: Wilkins and Wilkins; 1973
497. **Sheehan HL. 1940.** The pathology of acute yellow atrophy and delayed chloroform poisoning. *Journal of Obstetrics and Gynaecology* 47:49 – 62.
498. **Shellock FG and Kanal E.** Safety of magnetic resonance imaging contrast agents. *J Magn Reson Imaging* 1999; 10: 477–84.
499. **Shennan AH, Waugh J.** The measurement of blood pressure and proteinuria in pregnancy. In: Critchly H, MacLean A, Poston L, Walker J, editors. *Pre-eclampsia*. London, England: RCOG Press; 2003:305–24.
500. **Sherman KE.** *Alanine aminotransferase in clinical practice*. *Arch Intern Med* 1991;151:260–265.
501. **Shirin H, Sadan O, Shevah O et al.** Positive serology for *Helicobacter pylori* and vomiting in the pregnancy. *Arch Gynecol Obstet* 2004; 270(1): 10–14.
502. **Sibai BH.** Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. *Am J Obstet Gynecol* 2004;190:1520–6.
503. **Sibai BM, Barton JR.** Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. *Am J Obstet Gynecol* 2007;196. 514:e1–9.

504. **Sibai BM, Caritis SN, Thon E, Klebanoff M, McNellis D, Rocco L, et al.** Prevention of preeclampsia with low-dose aspirin in healthy nulliparous women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med* 1993;39:1213–8.
505. **Sibai BM, Mercer BM, Schiff E, Friedman SA:** Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. *Am J Obstet Gynecol* 1994, 171:818-822.
506. **Sibai BM, Ramadan MK, Chari RS, Friedman SA.** Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. *Am J Obstet Gynecol* 1995; 172(1 Part 1):125–129.
507. **Sibai BM, Ramadan MK, Chari RS, Friedman SA.** Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. *Am J Obstet Gynecol* 1995;172(1 Part 1):125–129.
508. **Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA:** Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). *Am J Obstet Gynecol* 1993, 169:1000-1006.
509. **Sibai BM, Ramadan MK:** Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets. *Am J Obstet Gynecol* 1993, 168:1682-1687.
510. **Sibai BM, Taslimi MM, el-Nazer A, Amon E, Mabie BC, Ryan GM:** Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. *Am J Obstet Gynecol* 1986, 155:501-509.

511. **Sibai BM.** Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. *Obstet Gynecol* 2004;103:981–91.
512. **Sibai BM.** Imitators of severe pre-eclampsia/eclampsia. *Clin Perinatol* 2004;31:835–52, vii–viii.
513. **Sibai BM.** Preeclampsia as a cause of preterm and late preterm (near-term) births. *Semin Perinatol* 2006;13: 16–9.
514. **Sibai BM:** Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. *Obstet Gynecol* 2004, 103:981-991.
515. **Sibai BM:** Imitators of severe pre-eclampsia/eclampsia. *Clin Perinatol* 2004, 31:835-852.
516. **Sibai BM:** The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? *Am J Obstet Gynecol* 1990, 162:311-316.
517. **Simic M, Tasic M, Stojiljkovic G, Draskovic D, Vukovic R:** HELLP syndrome as a cause of unexpected rapid maternal death – a case report and review of the literature. *Int J Legal Med* 2005, 119:103-106.
518. **Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ.** Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. *Eur J Clin Pharmacol* 2003; 58: 669–75.
519. **Sims HF, Brackett JC, Powell CK, Treem WR, Hale DE, Bennett MJ, Gibson B, Shapiro S, Strauss AW.** The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. *Proc Natl Acad Sci USA* 1995;92:841– 845.

520. **Singh S, Mohanty A, Joshi YK, Deka D, Mohanty S, Panda SK.** Mother-to-child transmission of hepatitis E virus infection. *Indian J Pediatr* 2003; 70: 37–39.
521. **Singhal N, Amin HJ, Pollard JK, Tough SC, Johnston DW, Clark DJ, Sauve R:** Maternal haemolysis, elevated liver enzymes and low platelets syndrome: perinatal and neurodevelopmental neonatal outcomes for infants weighing less than 1250 g. *J Paediatr Child Health* 2004, 40:121-126.
522. **Siti Khadijah Ismail Louise Kenny.** Review on hyperemesis gravidarum 2007.
523. **Skurnik YD, Tcherniak A, Edlan K.** Ticlopidine- induced cholestatic hepatitis. *Ann Pharmacother* 2003; 37: 371–5.
524. **Smith C, Crowther C, Willson K et al.** A randomized controlled trial of ginger to treat nausea and vomiting in pregnancy. *Obstet Gynecol* 2004; 103(4): 639–645.
525. **Smith CC, Berstein LI, Davis RB, Rind DM, Shmerling RH.** Screening for statinrelated toxicity. The yield of transaminase and creatine kinase measurements in a primary care setting. *Arch Intern Med* 2003; 163: 688–92.
526. **Smoleniec JS, James DK.** Gastro-intestinal crises during pregnancy. *Dig Dis* 1993;11:313–324.
527. **Smulian JC, Shen-Schwarz S, Scorza WE, Kinzler WL, Vintzileos AM:** A clinicohistopathological comparison between HELLP syndrome and severe preeclampsia. *Journal of Maternal-Fetal and Neonatal Medicine* 2004, 16:287-293.
528. **Sniderman AD.** Is there value in liver function test and creatine phosphokinase monitoring with statin use? *Am J Cardiol* 2004; 94: 30F–4F.

529. **Soh Y, Yasuhi I, Nakayama D, Ishimaru T:** A case of postpartum cerebellar infarction with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome. *Gynecol Obstet Invest* 2002, 53:240-242.
530. **Soller RW, Stander H.** Association between salicylates and Reye's syndrome. *JAMA* 1983; 249: 883.
531. **Sookoian S, Castano G, Burgueno A, et al.** Association of the multidrugresistance- associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. *J Hepatol* 2008; 48:125–132. This study demonstrates another variant of the gene mutation and its association with ICP.
532. **Spencer JD, Latt N, Beeby PJ, et al.:** Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. *J Viral Hepat* 1997, 4:395–409.
533. **Sreenivasan MA, Banerjee K, Pandya PG, et al.** Epidemiological investigations of an outbreak of infectious hepatitis in Ahmedabad city during 1975–76. *Indian J Med Res* 1978; 67: 197–206.
534. **Stedman C. Herbal hepatotoxicity.** *Semin Liver Dis* 2002; 22: 195–206.
535. **Stingrub,** Pregnancy and liver disease 2004, 22: 195–206.
536. **Steininger C, Kundi M, Jatzko G, et al.:** Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. *J Infect Dis* 2003, 187:345–351.
537. **Steven MM, Buckley JD, Mackay IR.** Pregnancy in chronic active hepatitis. *Q J Med* 1979; 48: 519–31.
538. **Steven MM.** Pregnancy and liver disease. *Gut* 1981; 22: 592–614.
539. **Stewart MW, Brazis PW, Guier CP, Thota SH, Wilson SD:** Purtscher-

540. **Stickel F, Patsenker E, Schuppan D.** Herbal hepatotoxicity. *J Hepatol* 2005; 43: 901–10.
541. **Stickel F, Schuppan D.** Herbal medicine in the treatment of liver disease. *Dig Liver Dis* 2007; 39: 293–304.
542. **Stiles AD:** Prenatal corticosteroids – early gain, long-term questions. *N Engl J Med* 2007, 357:1248-1250.
543. **Stolk MF, Becx MC, Kuypers KC, et al.** Severe hepatic side effects of ezetimibe. *Clin Gastroenterol Hepatol* 2006; 4: 908– 11.
544. **Strader DB, Bacon BR, Lindsay KL, et al.** Use of complementary and alternative medicine in patients with liver disease. *Am J Gastroenterol* 2002; 135: 262–8.
545. **Strader DB, Wright T, Thomas DL, Seeff LB.** Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; 39: 1147–71..
546. **Stubbs TM, Lazarchick J, Van Dorsten JP, Cox J, Loadholt CB:** Evidence of accelerated platelet production and consumption in nonthrombocytopenic preeclampsia. *Am J Obstet Gynecol* 1986, 155:263-265.
547. **Su G-G, Pan K-H, Zhao N-F, et al.** Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. *World J Gastroenterol* 2004; 10: 910–2.
548. **Sukenik-Halevy R, Ellis MH, Fejgin MD:** Management of immune thrombocytopenic purpura in pregnancy. *Obstet Gynecol Surv* 2008, 63:182-188.
549. **Sulkowski MS, Thomas DL, Mehta SH, et al.** Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA* 2000; 283: 74–80.

550. **Sulkowski MS, Thomas DL, Mehta SH, et al.** Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: a role of hepatitis C and B infections. *Hepatology* 2002; 35: 182–9.
551. **Sulkowski MS.** Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. *Clin Infect Dis* 2004; 38(Suppl. 2): S90–7.
552. **Sulkowski MS.** Viral hepatitis and HIV coinfection. *J Hepatol* 2008; 48: 353–67.
553. **Suzuki S, Watanabe S, Araki T. 2001.** Acute fatty liver of pregnancy at 23 weeks of gestation. *British Journal of Obstetrics and Gynaecology* 108:223 – 224.
554. **Svenningsen R, Morken NH, Kahn JA:** Corticosteroids in the treatment of HELLP-syndrome? *Tidsskr Nor Laegeforen* 2006, 126:2253-2256.
555. **Swallow BL, Lindow SW, Masson EA et al.** Psychological health in early pregnancy: relationship with nausea and vomiting. *J Obstet Gynaecol* 2004; 24(1): 28–32.
556. **Tan JY, Loh KC, Yeo GS et al.** Transient hyperthyroidism of hyperemesis gravidarum. *Br J Obstet Gynaecol* 2002; 109(6): 683–688.
557. **Tan PC, Jacob R, Quek KF et al.** The fetal sex ratio and metabolic, biochemical, haematological and clinical indicators of severity of hyperemesis gravidarum. *Br J Obstet Gynaecol* 2006; 113(6): 733–737.
558. **Tandon BN, Joshi YK, Jain SK, Gandhi BM, Mathiesan LR, Tandon HD.** An epidemic of non-A, non-B hepatitis in north India. *Indian J Med Res* 1982; 75: 739–44.

559. **Tarantino G, Conca P, Basile V, et al.** A prospective study of acute drug induced liver injury in patients suffering from non-alcoholic fatty liver disease. *Hepatol Res* 2007; 37: 410–5.
560. **Tarazi EM, Harter JG, Zimmerman HJ, et al.** Sulindac associated hepatic injury. Analysis of 91 cases reported to the Food and Drug Administration. *Gastroenterology* 1993; 104: 569–74.
561. **ter Borg MJ, Leemans WF, de Man RA, Janssen HLA.** Exacerbation of chronic hepatitis B infection after delivery. *J Vir Hepat* 2008; 15: 37–41.
562. **Tipranavir** (Aptivus) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2007.
563. **Tolman KG.** The liver and lovastatin. *Am J Cardiol* 2002; 89: 1374–80.
564. **Torti C, Costarelli S, De Silvestri A, et al.** Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. *Drug Saf* 2007; 30: 1161–9.
565. **Tostmann A, Boeree MJ, Aarnoutse RE, et al.** Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. *J Gastroenterol Hepatol* 2008; 23: 192–202.
566. **Towers CV, Asrat T, Rumney P.** The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. *Am J Obstet Gynecol* 2001; 184: 1514–8.
567. **Tran TT, Keffe EB.** Management of the pregnant hepatitis B patient. *Curr Hep B Rep* 2008; 2: 43–8.
568. **Tranquilli AL, Giannubilo SR, Tedeschi E, Bezzeccheri V, Suzuki H, Menegazzi M:** Placental expression of nitric oxide synthase during HELLP syndrome: the correlation with maternal-fetal Doppler velocimetry. *Acta Obstet Gynecol Scand* 2005, 84:849-853.

569. **Tredger JM, Smith HM, Read RB, et al.** Effects of ethanol ingestion on the hepatotoxicity and metabolism of paracetamol in mice. *Toxicology* 1985; 36: 341–52.
570. **Treem WR, Rinaldo P, Hale DE, Stanley CA, Millington DS, Hyams JS, Jackson S, Turnbull DM.** Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. *Hepatology* 1994;19:339–345.
571. **Trogstad LI, Stoltenberg C, Magnus P et al.** Recurrence risk in hyperemesis gravidarum. *Br J Obstet Gynaecol* 2005; 112(12): 1641–1645.
572. **Tsang IS, Katz VL & Wells SD.** Maternal and fetal outcomes in hyperemesis gravidarum. *Int J Gynaecol Obstet* 1996 Dec; 55(3): 231–235.
573. **Tse KY, Lo LF, Lao T.** The impact of maternal HBsAg carrier status on pregnancy outcomes: a case–control study. *J Hepatol* 2005; 43: 771–5.
574. **Tsega E, Hansson BG, Krawczynski K, Nordenfelt E.** Acute sporadic viral hepatitis in Ethiopia: causes, risk factors, and effects on pregnancy. *Clin Infect Dis* 1992; 14: 961–65.
575. **Tyni T, Ekholm E, Pihko H. 1998.** Pregnancy complications are frequent in long chain 3 hydroxyacyl coenzyme A dehydrogenase deficiency. *American Journal of Obstetrics and Gynecology* 178:603 – 608.
576. **Ucar M, Mjorndal T, Dahlqvist R.** HMGCoA reductase inhibitors and myotoxicity. *Drug Saf* 2000; 22: 441–57.
577. **Ungo JR, Hones D, Ashkin D, et al.** Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. *Am J Respir Crit Care Med* 1998; 157: 1871–6.

578. **Usta IM, Barton JR, Amen EA, Gonzalez A, Sibai BM. 1994.** Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourteen cases. *American Journal of Obstetrics and Gynecology* 171:1342 – 1347
579. **Vaisman N, Kaidar R, Levin I et al.** Nasojejunal feeding in hyperemesis gravidarum – a preliminary study. *Clin Nutr* 2004; 23(1): 53–57.
580. **Vajro P, Lofrano MM, Fontanella A, Fortunato G.** Immunoglobulin complexed AST (“macro-AST”) in an asymptomatic child with persistent hypertransaminasemia. *J Pediatr Gastroenterol Nutr* 1992;15:458–460.
581. **Vamvakopoulos JE, Kountouri M, Marshall T, Greenfield SM.** Lifestyle or life-saving medicines? A primary Healthcare Professional and Consumer Opinion Survey on over-the-counter statins. *Ann Pharmacother* 2008; 42: 413–20.
582. **Van Dam PA, Renier M, Baekelandt M, Buytaert P, Uyttenbroeck F:** Disseminated intravascular coagulation and the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia. *Obstet Gynecol* 1989, 73:97-102.
583. **Van Pampus MG, Wolf H, Westenberg SM, Post JA van der, Bonsel GJ, Treffers PE:** Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with preeclampsia without HELLP syndrome. *Eur J Obstet Gynecol Reprod Biol* 1998, 76:31-36.
584. **van Runnard Heimel PJ, Franx A, Schobben AF, Huisjes AJ, Derks JB, Bruinse HW:** Corticosteroids, pregnancy, and HELLP syndrome: a review. *Obstet Gynecol Surv* 2005, 60:57-70.

585. **van Stuijvenberg ME, Schabort I, Labadarios D et al.** The nutritional status and treatment of patients with hyperemesis gravidarum. *Am J Obstet Gynecol* 1995; 172(5): 1585–1591.
586. **van Zonneveld M, van Nunen AB, Niesters HGM, et al.** Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. *J Virol Hepatol* 2003; 10: 294–7..
587. **Verberg MF, Gillott DJ, Al-Fardan N et al.** Hyperemesis gravidarum, a literature review. *Hum Reprod Update* 2005; 11(5): 527–539.
588. **Verucchi G, Calza L, Manfredi R, et al.** Incidence of liver toxicity in HIVinfected patients receiving isolated dual nucleoside analogue antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003; 33: 546–8.
589. **Vidaeff AC, Yeomans ER:** Corticosteroids for the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP): what evidence? *Minerva Ginecol* 2007, 59:183-190.
590. **Vigil-De GP:** Addition of platelet transfusions to corticosteroids does not increase the recovery of severe HELLP syndrome. *Eur J Obstet Gynecol Reprod Biol* 2006, 128:194-198.
591. **Villar J, Abalos E, Nardin JM, Merialdi M, Carroli G.** Strategies to prevent and treat preeclampsia. Evidence from randomized controlled trials. *Semin Nephrol* 2004;24:607–15.
592. **Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N, et al.** World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. *Am J Obstet Gynecol* 2006;194:639–49.
593. **Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, et al.** Preeclampsia, gestational hypertension and intrauterine

growth restriction, related or independent conditions? *Am J Obstet Gynecol* 2006;194:921.

594. **Villar J, Say L, Gulmezoglu AM, Marialdi M, Lindheimer MD, Betran AP, et al.** Pre-eclampsia eclampsia: a health problem for 2000 years. In: Critchly H, MacLean A, Poston L, Walker J, editors. Pre-eclampsia. London, England: RCOG Press; 2003:189–207.
595. **Visser W, Wallenburg HC:** Temporising management of severe pre-eclampsia with and without the HELLP syndrome. *Br J Obstet Gynaecol* 1995, 102:111-117.
596. **von Dadelszen P, Magee LA, Roberts JM.** Subclassification of preeclampsia. *Hypertens Pregnancy* 2003;22: 143–8.
597. **von Dadelszen P, Magee LA.** Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. *J Obstet Gynaecol Can* 2002;24:941–5.
598. **von Dadelszen P, Menzies J, Gilgoff S, Xie F, Douglas MJ, Sawchuck D, et al.** Evidence-based management for preeclampsia. *Front Biosci* 2007;12:2876–89.
599. **Vuppalanchi R, Liangpunsakul S, Chalasani N.** Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? *Am J Gastroenterol* 2007; 102: 558–62.
600. **Vuppalanchi R, Teal E, Chalasani N.** Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. *Am J Med Sci* 2005; 329: 62– 5.
601. **Vuppalanchi R., Liangpunsakul S., Chalasani N. Etiology of New-Onset Jaundice: How Often Is It Caused by Idiosyncratic . Drug-Induced Liver Injury in The United States? Am. J. Gastroenterol. (2007) 102 558–562.**

602. **Vutyavanich T, Kraissarin T & Ruangsri R.** Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. *Obstet Gynecol* 2001; 97(4): 577–582.
603. **Wagner M, Zollner G, Trauner M.** New molecular insights into the mechanisms of cholestasis. *J Hepatol* 2009; 51:565–580. A review of cell and molecular mechanisms of ICP.
604. **Walgren J.L., Mitchell M.D., Thompson D.C.** Role of metabolism in drug-induced idiosyncratic hepatotoxicity. *Crit. Rev. Toxicol.* (2005) 35 325–361.
605. **Walker SP, Wein P, Ihle BU:** Severe folate deficiency masquerading as the syndrome of hemolysis, elevated liver enzymes, and low platelets. *Obstet Gynecol* 1997, 90:655-657.
606. **Walshe JM.** The management of pregnancy in Wilson's disease treated with trientine. *Q J Med* 1986; 58: 81–87.
607. **Wang CH, Leung CH, Liu SC, Chung CH.** Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease. *J Formos Med Assoc* 2006; 105: 743–52.
608. **Wang J, Zhu Q, Zhang X.** Effect of delivery mode on maternal–infant transmission of hepatitis B virus by immunoprophylaxis. *Chin Med J* 2002; 115: 1510–2.
609. **Wang JS, Zhu QR, Wang XH.** Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. *Int J Clin Pract* 2003; 57: 100–2.
610. **Wapner RJ, Sorokin Y, Mele L, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Malone F, Caritis SN, et al.:** Long-term outcomes after repeat doses of antenatal corticosteroids. *N Engl J Med* 2007, 357:1190-1198.

611. **Wapner RJ, Sorokin Y, Thom EA, Johnson F, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, et al.** Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. *Am J Obstet Gynecol* 2006, 195:633-642.
612. **Ward C, Tudor-Williams G, Cotzias T, et al.** Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. *Gut* 2000, 47:277–280.
613. **Waring WS, Stephen AF, Malkowska AM, et al.** Acute ethanol coingestion confers a lower risk of hepatotoxicity after deliberate acetaminophen overdose. *Acad Emerg Med* 2008; 15: 54–8.
614. **Wasmuth HE, Glantz A, Keppeler H, et al.** Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. *Gut* 2007; 56:265– 270..
615. **Watkins P.B.** Idiosyncratic liver injury: challenges and approaches. *Toxicol. Pathol.* (2005) 33 1–5. .
616. **Watkins PB, Kaplowitz N, Slattery JT, et al.** Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. *JAMA* 2006; 296: 87– 93.
617. **Weinstein L:** Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. 1982. *Am J Obstet Gynecol* 2005, 193:859.
618. **Whitehead M.W., Hainsworth I., Kingham J.G.C.** The causes of obvious jaundice in South West Wales: 2000. *Gut.* (2001) 48 409–413.
619. **Whitehead M.W., Hawkes N.D., Hainsworth I., Kingham J.G.C.** A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. *Gut.* (1999) 45 129–133.

620. **Whitehead TP, Clarke CA, Whitfield AG.** Biochemical and hematological markers of alcohol intake. *Lancet* 1978;1: 978–981.
621. **Whitelaw A, Thoresen M:** Antenatal steroids and the developing brain. *Arch Dis Child Fetal Neonatal Ed* 2000, 83:F154-F157.
622. **Whitfield JB, Pounder RE, Neale G, Moss DW.** Serum gglutamyl transpeptidase activity in liver disease. *Gut* 1972;13:702–708.
623. **Why Mothers Die 2000–2002.** London: Confidential Enquiry into Maternal and Child Health, 2004.
624. **Wicke C, Pereira PL, Neeser E, Flesch I, Rodegerdts EA, Becker HD:** Subcapsular liver hematoma in HELLP syndrome: Evaluation of diagnostic and therapeutic options – a unicenter study. *Am J Obstet Gynecol* 2004, 190:106-112.
625. **Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M.** Mapping the theories of preeclampsia and the role of angiogenic factors. *Obstet Gynecol* 2007;109:168–80.
626. **Wilke G, Rath W, Schutz E, Armstrong VW, Kuhn W:** Haptoglobin as a sensitive marker of hemolysis in HELLP-syndrome. *Int J Gynaecol Obstet* 1992, 39:29-34.
627. **Willetts KE, Ekangaki A & Eden JA.** Effect of a ginger extract on pregnancy-induced nausea: a randomized controlled trial. *Aust N Z J Obstet Gynaecol* 2003; 43(2): 139–144.
628. **Williams GM, Iatropoulos MJ.** Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. *Toxicol Pathol* 2002; 30: 41–53.
629. **Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B.** Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. *Ann Intern Med* 1998; 128: 111–14.

630. **Wong S, Chan LY, Yu V, et al.** Hepatitis B carrier and perinatal outcome in singleton pregnancy. *Am J Perinatol* 1999; 16: 485–8.
631. **Wong VC, Lee AKY, Ip HMM.** Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. *Br J Obstet Gynaecol* 1980; 87: 958–65.
632. **Wong WM, Wu PC, Yuen MF, et al.** Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. *Hepatology* 2000; 31: 201–6
633. **Wu MS, Chan P, Lien GS.** Ticlopidine-induced severe cholestatic hepatitis. *Zhonghua Yi Xue Za Zhi (Taipei)* 2000; 63: 663–6.
634. **Xia Y, Ramin SM, Kellems RE.** Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. *Hypertension* 2007;50:269–75.
635. **Xiao XM, Li AZ, Chen X, Zhu YK, Miao J.** Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. *Int J Gynecol Obstet* 2007; 96: 167–70.
636. **Xu DZ, Yan YP, Choi BC, et al.** Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case–control study. *J Med Virol* 2002; 67: 20–6.
637. **Xu Q, Xiao L, Lu X-B, Zhang Y-X, Cai X.** A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. *World J Gastroenterol* 2006; 12: 3434–7.
638. **Xu WM, Cui YT, Wang L, et al.** Efficacy and safety of lamivudine in late pregnancy for the prevention of mother– child transmission of hepatitis B: a multicentre, randomized, double-blind, placebo-controlled study [abstract]. *Hepatology* 2004; 40: 272A.

639. **Yalcin OT, Sener T, Hassa H, Ozalp S, Okur A:** Effects of postpartum corticosteroids in patients with HELLP syndrome. *Int J Gynaecol Obstet* 1998, 61:141-148.
640. **Yang Y-B, Li X-M, Shi Z-J, Ma L.** Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. *World J Gastroenterol* 2004; 10:2305–6.
641. **Yang Z, Zhao Y, Bennett MJ et al.** Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. *Am J Obstet Gynecol* 2002;187:715–20.
642. **Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeiki K, Kobayashi K, Irie Y.** Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. *Gastroenterology* 1995;109:1295– 1300.
643. **Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH:** Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. *N Engl J Med* 2004, 350:1304-1313.
119. **Thiagarajah S, Bourgeois FJ, Harbert GM Jr, Caudle MR:** Thrombocytopenia in preeclampsia: associated abnormalities and management principles. *Am J Obstet Gynecol* 1984, 150:1-7.
644. **Yeung LT, King SM, Roberts EA:** Mother-to-infant transmission of hepatitis C virus. *Hepatology* 2001, 34:223–229. This is a review of published literature using weighted averages to assess risk factors for vertical transmission.
645. **Yoshimura M & Hershman JM.** Thyrotropic action of human chorionic gonadotropin. *Thyroid* 1995; 5(5): 425–434.
646. **Yost NP, McIntire DD, Wians Jr. FH et al.** A randomized, placebo-controlled trial of corticosteroids for hyperemesis due to pregnancy. *Obstet Gynecol* 2003; 102(6): 1250–1254.

647. **Yu H, Zhu QR, Gu SQ, et al.** Relationship between IFN-gamma gene polymorphism and susceptibility to intrauterine HBV infection. *World J Gastroenterol* 2006; 12: 2928–31.
648. **Yuan J, Lin J, Xu A, et al.** Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. *J Virol Hepatol* 2006; 13: 597–604.
649. **Yücesoy , Ozkan S, Bodur H, Tan T, Caliskan E, Vural B, Corakci A:** Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. *Arch Gynecol Obstet* 2005, 273:43-49.
650. **Zachariae H.** Liver biopsies and methotrexate. A time for reconsideration?. *J Am Acad Dermatol* 2000; 42: 531–4.
651. **Zandi-Nejad K, Luyckx VA, Brenner BM.** Adult hypertension and kidney disease: the role of fetal programming. *Hypertension* 2006;47:502–8.
652. **Zanetti AR, Tanzi E, Newell ML:** Mother-to-infant transmission of hepatitis C virus. *J Hepatol* 1999, 31(Suppl 1):96–100.
653. **Zanetti AR, Tanzi E, Paccagnini S, et al.:** Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. *Lancet* 1995, 345:289–291.
654. **Zanetti AR, Tanzi E, Romano L, et al.:** A prospective study on mother-to-infant transmission of hepatitis C virus. *Intervirology* 1998, 41:208–212.
655. **Zapata R, Sandoval L, Palma J, et al.** Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. *Liver International* 2005; 25:548–554.

656. **Zapater P, Lasso delaVegaMC, Horga JF, et al.** Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. *Aliment Pharmacol Ther* 2004; 20: 29–36.
657. **Zecca E, Costa S, Lauriola V, et al.** Bile acid pneumonia: a ‘new’ form of neonatal respiratory distress syndrome? *Pediatrics* 2004; 114:269–272.
658. **Zecca E, De Luca D, Barbato G, et al.** Predicting respiratory distress syndrome in neonates from mothers with intrahepatic cholestasis of pregnancy. *Early Hum Dev* 2008; 84:337–341. This is an excellent review explaining the pathophysiology of RDS in neonates born to women with ICP.
659. **Zecca E, De Luca D, Baroni S, et al.** Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study. *Pediatrics* 2008; 121:e146– e149. This is an excellent review offering a hypothesis for the development of RDS in neonates born to women with ICP.
660. **Zeeman GG, Fleckenstein GL, Twinckler DM, Cunningham FG.** Cerebral infarction in preeclampsia. *Am J Obstet Gynecol* 2004;190:714–20.
661. **Zeeman GG, Hatab MR, Twickler DM.** Increased cerebral blood flow in preeclampsia with magnetic resonance imaging. *Am J Obstet Gynecol* 2004;191: 1425–9.
662. **Zeeman GG, Vollaard ES, Alexander JM , McIntire DD, Cunningham FG.** “Delta preeclampsia”—a hypertensive encephalopathy in “normotensive” women. *Am J Obstet Gynecol* 2007;197:S140.
663. **Zeidman LA, Videnovic A, Bernstein LP, Pellar CA:** Lethal pontine hemorrhage in postpartum syndrome of hemolysis, elevated

- liver enzyme levels, and low platelet count. *Arch Neurol* 2005; 62:1150-1153.
664. **Zein CO, Abu-Lebdeh H, Zein NN:** Spontaneous clearance of chronic hepatitis C during pregnancy. *Am J Gastroenterol* 2001; 96:3044–3045.
665. **Zhang J, Villar J, Sun W, Meraldi M, Andel-Aleem H, Mathai M, et al.** Blood pressure dynamics during pregnancy and spontaneous preterm labor. *Am J Obstet Gynecol* 2007;197. 162e1–e6.
666. **Zhu QR, Ge YL, Gu SQ, et al.** Relationship between cytokines gene polymorphism and susceptibility to hepatitis B virus intrauterine infection. *Chin Med J* 2005; 118: 160
667. **Zimmerman HJ, Maddrey WC.** Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. *Hepatology* 1995; 22: 767–73.
668. **Zimmerman HJ.** Effects of alcohol on other hepatotoxins. *Alcohol Clin Exp Res* 1986; 10: 3–15.
669. **Zuccotti GV, Ribero ML, Giovannini M, et al.** Effect of hepatitis C genotype on mother-to-infant transmission of virus. *J Pediatr* 1995, 127:278–280.
670. **Zucker SD, Qin X, Rouster SD, et al.** Mechanism of indinavir-induced hyperbilirubinemia. *Proc Natl Acad Sci USA* 2001; 98: 12671–6.
671. **Zucker SD.** Is it helpful to consider the hanging LCHAD in pregnancy-associated liver disease? *Gastroenterology* 2003;124: 1548–50.
672. **Zuckerman AJ.** Effect of hepatitis B virus mutants on efficacy of vaccination. *Lancet* 2000; 355: 1382–4.

673. *Zuckerman J, van Hattum J, Cafferkey M, et al.* Should hepatitis B vaccination be introduced into childhood immunization programmes in northern Europe? *Lancet Infect. Dis* 2007; 7: 410–9.